Progressive Pseudorheumatoid Arthropathy of Childhood

Mendelian MONDO:0008827 Pathograph 11 Show in embeddings browser Skeletal Dysplasia Spondyloepiphyseal Dysplasia

Progressive pseudorheumatoid arthropathy of childhood (PPRD) is an autosomal recessive skeletal dysplasia caused by biallelic loss-of-function variants in CCN6 (WISP3). Articular cartilage degenerates progressively in the complete absence of inflammation, producing symmetric joint stiffness and enlargement, prominent interphalangeal joints, platyspondyly, short stature and early secondary osteoarthritis, with onset typically between three and six years. The defining clinical problem is not the arthropathy but the mistake it invites. PPRD looks like juvenile idiopathic arthritis and is routinely treated as such, sometimes for years, with drugs that cannot work: ESR, CRP, rheumatoid factor and ANA are normal, and there is nothing inflammatory for an immunosuppressant to act on. In one Turkish cohort the median age at symptom onset was four years and at diagnosis 9.7. The cost of that delay is measurable — 47.7% of those patients lost independent walking at a median age of twelve. There is no disease-modifying therapy. Joint arthroplasty for end-stage large joints is the one intervention with substantial outcome data behind it.

Ask OpenScientist

Ask a research question about Progressive Pseudorheumatoid Arthropathy of Childhood. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
1
Inheritance
5
Pathophys.
13
Phenotypes
2
Gaps
11
Pathograph
1
Genes
3
Variants
9
Medical Actions
2
Differentials
3
References
1
Deep Research
📘

Definitions

1
PPRD diagnostic criteria
Established in a proband with characteristic radiographic features and/or biallelic pathogenic CCN6 variants. Clinical ascertainment rests on progressive stiffness of multiple joints, characteristic wide metaphyses of the interphalangeal joints, and platyspondyly.
CASE_DEFINITION Disease-level ascertainment, and separation from inflammatory arthritis.
Show evidence (2 references)
PMID:26610319 SUPPORT Human Clinical
"The diagnosis of PPRD is established in a proband with characteristic radiographic features and/or biallelic pathogenic variants in CCN6 identified by molecular genetic testing."
GeneReviews states the diagnostic criteria.
PMID:34919662 SUPPORT Human Clinical
"The patients with progressive stiffness of multiple joints, characteristic wide metaphysis of interphalangeal (IP) joints and platyspondyly were clinically diagnosed with PPRD."
Gives the clinical triad used for ascertainment in a large cohort.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"PPRD is inherited in an autosomal recessive manner."
GeneReviews states the mode of inheritance.
?

Discussions and Knowledge Gaps

2
Wisp3-deficient mice have no apparent phenotype. What does a species with no disease tell us about the human mechanism, and what model should replace the mouse for preclinical work?
HUMAN MODEL MISMATCH no_mouse_model_for_ccn6_loss
Attached to
pathophysiology#Loss of CCN6 Modulation of BMP and Wnt Signaling
This is a translational block rather than a gap in evidence. Loss of Wisp3 in the mouse produces no apparent phenotype, and neither does overexpression — so the standard preclinical species is uninformative for a disease that is fully penetrant in humans. Two readings are open. Either mouse cartilage has a redundancy that human articular cartilage lacks, in which case the interesting biology is what compensates; or the human phenotype depends on mechanical loading histories, growth duration or joint geometry that a mouse does not reproduce. The zebrafish work is currently the only in vivo system where CCN6 loss does something, and it reports pharyngeal cartilage morphology rather than progressive articular degeneration. Until this is resolved there is no animal system in which a disease-modifying therapy could be tested, which is a plausible part of why none exists.
Show evidence (1 reference)
PMID:17823661 SUPPORT Model Organism
"in mice there is no apparent phenotype caused by Wisp3 deficiency or overexpression"
The negative result that constitutes the mismatch.
What are the intermediate steps between deregulated BMP/Wnt signalling and progressive loss of human articular cartilage in PPRD?
KNOWLEDGE GAP bmp_wnt_to_cartilage_loss_intermediates
Attached to
pathophysiology#Failure of Articular Chondrocyte Matrix Homeostasis
Both ends of this chain are well supported and the middle is not. CCN6's inhibition of BMP and Wnt signalling is demonstrated by gain-of-function in zebrafish; progressive articular cartilage loss is documented radiographically in patients. Between them sit at least three competing proposals — loss of matrix-synthetic drive on type II collagen and aggrecan, loss of superoxide dismutase-dependent antioxidant protection, and increased chondrocyte IGF-1 sensitivity driving hypertrophic differentiation — none demonstrated in human articular cartilage. They are not mutually exclusive, which is part of why none has been excluded. The edge in this entry is typed INDIRECT_UNKNOWN_INTERMEDIATES for exactly this reason.
Show evidence (1 reference)
PMID:16480948 SUPPORT In Vitro
"WISP-3 may also promote superoxide dismutase expression and activity in chondrocytes"
One of the competing intermediate proposals, stated with the authors' own hedge.
⚙

Pathophysiology

5
Biallelic CCN6 Loss of Function
Genetic context CCN6 hgnc:12771 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns CCN6 (hgnc:12771). hgnc:12771 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION
Biallelic nonsense, frameshift, splice-site and missense variants abolish CCN6 function. Disease-causing amino-acid substitutions reduce the protein's signalling-inhibitory activity in a zebrafish assay.
Downstream
Loss of CCN6 Modulation of BMP and Wnt Signaling CCN6 normally inhibits BMP and Wnt signalling by binding BMP ligand and the Wnt co-receptors LRP6 and Frizzled; disease alleles reduce that inhibition.
Show evidence (1 reference)
PMID:37377052 SUPPORT Human Clinical
"PPRD occurs due to loss of function pathogenic variants in WISP3 (CCN6) gene, located on chromosome 6q22."
Names the gene and the loss-of-function mechanism defining this node.
Loss of CCN6 Modulation of BMP and Wnt Signaling
CCN6 is a secreted matricellular protein that binds BMP ligand and the Wnt co-receptors LRP6 and Frizzled. Loss of that binding removes a brake on both pathways in developing and mature cartilage.
BMP signaling pathway GO:0030509 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased BMP signaling pathway (GO:0030509). GO:0030509 is a biological process from the Gene Ontology. ↑ INCREASED Wnt signaling pathway GO:0016055 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Wnt signaling pathway (GO:0016055). GO:0016055 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Failure of Articular Chondrocyte Matrix Homeostasis Deregulated BMP/Wnt signalling in cartilage is proposed to disturb chondrocyte matrix maintenance, but the intermediate steps between the signalling change and cartilage loss are not established in human tissue.
Show evidence (1 reference)
PMID:17823661 SUPPORT Model Organism
"Overexpression of zebrafish Wisp3 protein inhibited bone morphogenetic protein (BMP) and Wnt signaling in developing zebrafish"
The inhibitory activity whose loss defines this node, demonstrated by gain-of-function in the zebrafish assay.
Failure of Articular Chondrocyte Matrix Homeostasis
WISP-3 acts on chondrocytes as an autocrine and paracrine ligand, upregulating type II collagen and aggrecan and promoting superoxide dismutase activity, so its loss removes both a matrix-synthetic and an antioxidant input. A separate proposal is that mutant WISP3 loses its ability to restrain IGF-1, increasing chondrocyte IGF-1 sensitivity and shifting cells toward hypertrophic differentiation. These are complementary hypotheses rather than an established sequence.
articular chondrocyte CL:1001607 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves articular chondrocyte (CL:1001607). CL:1001607 is a cell type from the Cell Ontology.
Downstream
Progressive Noninflammatory Articular Cartilage Loss Loss of chondrocyte matrix maintenance produces progressive narrowing of all articular spaces as cartilage is lost.
Show evidence (1 reference)
PMID:16480948 SUPPORT In Vitro
"WISP-3 may also promote superoxide dismutase expression and activity in chondrocytes"
Establishes an antioxidant function of the protein in the affected cell type. The authors' own hedge is preserved.
Progressive Noninflammatory Articular Cartilage Loss
Articular cartilage is lost progressively across multiple joints with no inflammatory component. The absence of inflammation is not incidental — it is what makes anti-inflammatory and immunosuppressive treatment futile, and it is the feature that should separate PPRD from juvenile idiopathic arthritis at the bedside.
Downstream
Joint Contracture, Deformity and Loss of Ambulation Cartilage loss across large joints and the spine causes contractures, gait disturbance and spinal deformity, culminating for many patients in loss of independent walking.
Show evidence (2 references)
PMID:26610319 SUPPORT Human Clinical
"Progressive pseudorheumatoid dysplasia (PPRD) is a skeletal dysplasia characterized by predominant involvement of articular cartilage with progressive joint stiffness and enlargement in the absence of inflammation."
States both the tissue target and the absence of inflammation.
PMID:22791401 SUPPORT Human Clinical
"however, signs of inflammation are absent and anti-inflammatory treatment is of little help"
Connects the absence of inflammation to the failure of anti-inflammatory therapy.
Joint Contracture, Deformity and Loss of Ambulation
The functional endpoint. Waddling gait occurred in 97.7% of the Turkish cohort and 47.7% lost independent walking at a median age of twelve.
Show evidence (1 reference)
PMID:34919662 SUPPORT Human Clinical
"Waddling gait occurred in 97.7% of the patients. A total of 47.7% lost independent walking ability at the median age of 12 years."
Quantifies both the gait abnormality and the loss of ambulation.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Progressive Pseudorheumatoid Arthropathy of Childhood Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Limbs 3
Prominent interphalangeal joints HP:0006237 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Prominent interphalangeal joints (HP:0006237). HP:0006237 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:34919662 SUPPORT Human Clinical
"The initial symptom in the early-onset group was genu varum deformity, while it was widening of IP joints in the classical group."
Identifies interphalangeal widening as the presenting sign of classical disease.
PMID:22791401 SUPPORT Human Clinical
"Bony enlargement at the interphalangeal joints progresses leading to camptodactyly."
States that the enlargement is bony, which is the discriminating feature.
Genu varum HP:0002970 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Genu varum (HP:0002970). HP:0002970 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34919662 SUPPORT Human Clinical
"We observed that genu varum deformity before the age of 3 years was an early sign for PPRD"
Identifies genu varum as the early-onset presenting sign.
Contractures of the small joints of the hands Finger joint contracture HP:0034681 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Finger joint contracture (HP:0034681). HP:0034681 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22987568 SUPPORT Human Clinical
"Swelling of small joints of hands and contractures are the most common presenting features."
Identifies small-joint swelling and contracture as the commonest presentation in a 35-patient series.
Musculoskeletal 8
Joint stiffness VERY_FREQUENT HP:0001387 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint stiffness (HP:0001387), qualified as course progressive. HP:0001387 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"Progressive pseudorheumatoid dysplasia (PPRD) is a skeletal dysplasia characterized by predominant involvement of articular cartilage with progressive joint stiffness and enlargement in the absence of inflammation."
Names progressive joint stiffness as a defining feature.
Platyspondyly HP:0000926 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Platyspondyly (HP:0000926). HP:0000926 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22791401 SUPPORT Human Clinical
"Platyspondyly develops in late childhood and can be the first clue to the diagnosis."
States the finding, its timing and its diagnostic value.
Osteoarthritis HP:0002758 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoarthritis (HP:0002758). HP:0002758 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"Pain due to secondary osteoarthritis may respond to nonsteroidal anti-inflammatory drugs."
GeneReviews names secondary osteoarthritis as a manifestation requiring treatment.
Osteoporosis HP:0000939 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22987568 SUPPORT Human Clinical
"Progressive pseudorheumatoid dysplasia (PPD) is a progressive skeletal syndrome characterized by stiffness, swelling and pain in multiple joints with associated osteoporosis in affected patients."
Names osteoporosis among the defining features.
Camptodactyly HP:0012385 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Camptodactyly (HP:0012385). HP:0012385 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22791401 SUPPORT Human Clinical
"Bony enlargement at the interphalangeal joints progresses leading to camptodactyly."
States camptodactyly as the consequence of the interphalangeal enlargement, which is why it is curated as a separate phenotype rather than folded into it.
Kyphosis HP:0002808 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Kyphosis (HP:0002808). HP:0002808 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22791401 SUPPORT Human Clinical
"Spine involvement develops in late childhood and adolescence leading to short trunk with thoracolumbar kyphosis."
Names thoracolumbar kyphosis and its timing.
Scoliosis HP:0002650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scoliosis (HP:0002650). HP:0002650 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"Over time, involvement of large joints and the spine causes significant joint contractures, gait disturbance, and scoliosis and/or kyphosis, resulting in abnormal posture and significant morbidity."
The same GeneReviews sentence that grounds the kyphosis and contracture phenotypes names scoliosis alongside them.
Joint contractures HP:0034392 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint contracture (HP:0034392). HP:0034392 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"Over time, involvement of large joints and the spine causes significant joint contractures, gait disturbance, and scoliosis and/or kyphosis, resulting in abnormal posture and significant morbidity."
GeneReviews names joint contractures among the accruing morbidity.
Nervous System 1
Waddling gait VERY_FREQUENT HP:0002515 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Waddling gait (HP:0002515). HP:0002515 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34919662 SUPPORT Human Clinical
"Waddling gait occurred in 97.7% of the patients."
Gives an explicit denominator-backed frequency in a genetically confirmed cohort.
Growth 1
Short stature HP:0004322 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short stature (HP:0004322). HP:0004322 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"Initially height is normal; however, short stature (<3rd centile) becomes evident in adolescence as the skeletal changes progress."
Establishes the phenotype and its late emergence.
🧬

Genetic Associations

1
CCN6
Gene: CCN6 hgnc:12771 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CCN6 (hgnc:12771). hgnc:12771 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (5 references)
PMID:37377052 SUPPORT Human Clinical
"PPRD occurs due to loss of function pathogenic variants in WISP3 (CCN6) gene, located on chromosome 6q22."
States the causal gene, its locus and the loss-of-function mechanism.
PMID:22987568 SUPPORT Human Clinical
"One missense mutation (c.1010G>A; p.Cys337Tyr) appears to be the most common in our population being seen in 10 unrelated families."
Establishes the Indian founder allele and its frequency.
PMID:34919662 SUPPORT Human Clinical
"c.156C>A(p.Cys52*) variant was found in 53.3% of the families."
Establishes the Turkish founder allele and its frequency.
+ 2 more references
Variants (3)
CCN6 c.1010G>A (p.Cys337Tyr)
The commonest Indian allele, homozygous in 10 unrelated families of 25.
CCN6 c.156C>A (p.Cys52*)
Nonsense allele found in 53.3% of Turkish families.
CCN6 c.624dupA (p.C209Mfs*21)
Chinese hotspot allele associated with later onset, more extensive joint involvement and elbow involvement.
💊

Medical Actions

9
Total Hip Arthroplasty
Action: total hip arthroplastyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is total hip arthroplasty, annotated with Arthroplasty (NCIT:C51691). NCIT:C51691 is a clinical intervention from the NCI Thesaurus. Ontology label: Arthroplasty NCIT:C51691
Platform: Surgery
The one intervention in PPRD with substantial outcome data. In four genetically confirmed patients undergoing one-stage bilateral total hip arthroplasty, Harris Hip Score rose from 39.67 to 91.67 and SF-36 from 19.67 to 71.33 over a mean 47.9 months, with no aseptic loosening. Named for the hip rather than for joint replacement generally: GeneReviews recommends arthroplasty for severe joint pain from advanced osteoarthritis without naming a joint, but every outcome figure quoted here is from hip series, so the broader name would claim a scope the evidence does not cover.
Mechanism Target:
BYPASSES Joint Contracture, Deformity and Loss of Ambulation — Arthroplasty replaces the destroyed joint rather than acting on the cartilage-loss process, so it restores function without altering the disease. That is why it is a BYPASSES link, and why it does not stop progression at other joints.
Show evidence (1 reference)
PMID:31876842 SUPPORT Human Clinical
"This study indicated that THA was effective to treat the PPD patients complicated with hip arthropathy with satisfactory clinical and radiological outcome after mid-term follow-up."
Reports the functional outcome of replacing the affected joint.
Show evidence (2 references)
PMID:31876842 SUPPORT Human Clinical
"Harris Hip Score increased from 39.67 ± 9.73 points preoperatively to 91.67 ± 4.32 points postoperatively (p < 0.05); Short Form 36 increased from 19.67 ± 1.53 points preoperatively to 71.33 ± 3.06 postoperatively (p < 0.05)."
Quantifies the functional and quality-of-life gain.
PMID:26610319 SUPPORT Human Clinical
"Severe joint pain due to advanced osteoarthritis is treated by joint arthroplasty."
GeneReviews states the indication.
Physical Therapy and Activity Modification
Action: physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Platform: Behavioral / lifestyle
Large-joint stiffness is managed by physical therapy, activity modification and walking aids; small-joint arthropathy by occupational therapy with adaptive devices. What the activity modification has to avoid is the reflexive orthopaedic response to a stiff, painful joint: GeneReviews lists immobilization, casting specifically, under agents and circumstances to avoid, so the caution belongs to this treatment rather than sitting in the entry's notes.
Show evidence (2 references)
PMID:26610319 SUPPORT Human Clinical
"Large joint stiffness is managed by physical therapy, activity modification, and walking aids."
GeneReviews states the supportive management for joint stiffness.
PMID:26610319 SUPPORT Human Clinical
"Agents/circumstances to avoid: Immobilization (e.g., casting)."
Grounds the activity-modification arm of this treatment: the modification that matters is avoiding immobilization.
NSAID Analgesia for Secondary Osteoarthritis
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Small molecule
NSAIDs are used for pain from secondary osteoarthritis. Note the careful distinction GeneReviews draws: they are for osteoarthritic pain, not for a disease process, and they do not modify the arthropathy.
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"Pain due to secondary osteoarthritis may respond to nonsteroidal anti-inflammatory drugs."
GeneReviews states the analgesic indication and hedges the response.
Vitamin D Supplementation in Documented Deficiency
Action: Nutritional SupportNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Nutritional Support (NCIT:C15433). NCIT:C15433 is a clinical intervention from the NCI Thesaurus. NCIT:C15433
Agent: calcitriol CHEBI:17823 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses calcitriol (CHEBI:17823). CHEBI:17823 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
GeneReviews recommends supplementation in those with vitamin D deficiency. This is correction of a coincident deficiency, not a disease-modifying therapy.
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"In those with vitamin D deficiency, supplementation is recommended."
GeneReviews states the indication, conditioned on documented deficiency.
Genetic Counseling and Carrier Testing
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Platform: Other
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"If the CCN6 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatalpreimplantation genetic testing are possible."
GeneReviews states the available reproductive genetic options.
Immunosuppressants and DMARDs
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Other
Modelled explicitly as an ineffective therapy rather than left as prose, because prescribing it is the characteristic clinical error in this disease and the entry should be queryable for that. There is no inflammatory process for these drugs to suppress; the misdiagnosis as juvenile idiopathic arthritis is what leads to years of them. Modality is OTHER rather than SMALL_MOLECULE because the class as prescribed here spans conventional synthetic DMARDs, corticosteroids and biologic agents, so no single platform describes it.
Mechanism Target:
MODULATES Progressive Noninflammatory Articular Cartilage Loss — No effect. Anti-inflammatory and immunosuppressive treatment does not act on this node because the node has no inflammatory component.
Show evidence (1 reference)
PMID:22791401 REFUTE Human Clinical
"however, signs of inflammation are absent and anti-inflammatory treatment is of little help"
Graded REFUTE against the claim that this treatment acts on the cartilage-loss node; the source states directly that it does not help.
Show evidence (1 reference)
PMID:22791401 REFUTE Human Clinical
"affected children often receive unnecessary anti-inflammatory and immunosuppressive treatments"
Records that these drugs are given and are unnecessary, which is the claim this treatment entry exists to carry.
Bracing for Scoliosis and Mild Kyphosis
Action: bracingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is bracing, annotated with Therapeutic Procedure (NCIT:C49236). NCIT:C49236 is a clinical intervention from the NCI Thesaurus. Ontology label: Therapeutic Procedure NCIT:C49236
Platform: Device
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"Scoliosis and mild kyphosis may be treated with bracing."
GeneReviews management recommendation for the spinal deformity.
Surgical Correction of Angular Lower-Limb Deformity
Action: orthopedic surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is orthopedic surgical procedure (NCIT:C16186). NCIT:C16186 is a clinical intervention from the NCI Thesaurus. Ontology label: Orthopedic Surgical Procedure NCIT:C16186
Platform: Surgery
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"Surgical treatment for angular deformities of the lower limbs per orthopedic surgeon."
GeneReviews management recommendation for limb deformity.
Occupational Therapy and Adaptive Devices
Action: occupational therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is occupational therapy (NCIT:C121351). NCIT:C121351 is a clinical intervention from the NCI Thesaurus. Ontology label: Occupational Therapy NCIT:C121351
Platform: Behavioral / lifestyle
Small-joint arthropathy is managed by an occupational therapist advising adaptive devices, activity modification and vocational training.
Show evidence (1 reference)
PMID:26610319 SUPPORT Human Clinical
"Small joint arthropathy is managed by an occupational therapist who may advise adaptive devices, modification of activity, and/or vocational training."
GeneReviews management recommendation for small-joint disease.
🔬

Biochemical Markers

1
Inflammatory markers and autoantibody serology (NORMAL)
Show evidence (1 reference)
PMID:36550675 SUPPORT Human Clinical
"Baseline biochemistry, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor and ANA, were within normal limits."
Documents the normal inflammatory and serological panel in a genetically confirmed case.
🔬

Diagnosis

4
Molecular genetic testing of CCN6
Definitive confirmation. Mutation analysis confirmed the diagnosis in 63 of 64 typical cases in one series, so a negative result in a clinically typical patient is unusual and should prompt the cDNA route below rather than abandonment of the diagnosis.
CCN6 molecular genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:22791401 SUPPORT Human Clinical
"Mutation analysis of WISP3 allowed the confirmation of the diagnosis in 63 out of 64 typical cases in our series."
Quantifies the diagnostic yield of sequencing in clinically typical patients.
Skin biopsy and fibroblast cDNA analysis for intronic splice variants
The step most likely to be missed. Intronic CCN6 variants causing splicing aberrations are detectable only in cDNA from fibroblasts, so a skin biopsy is indicated when genomic analysis is negative in an otherwise typical patient. Without it, a genuine case can be dismissed on a normal sequencing result.
skin biopsy for fibroblast cDNA analysis NCIT:C51692 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:22791401 SUPPORT Human Clinical
"Intronic mutations in WISP3 leading to splicing aberrations can be detected only in cDNA from fibroblasts and therefore a skin biopsy is indicated when genomic analysis fails to reveal mutations in individuals with otherwise typical signs and symptoms."
States both the limitation of genomic testing and the specific remedy.
Radiographic assessment
Radiographic signs are relatively mild, which is part of why the diagnosis is missed. The specific findings are platyspondyly in late childhood, phalangeal metaphyseal enlargement usually recognisable by ten years, large femoral heads with an acetabular lip overriding the head, and progressive narrowing of all articular spaces.
skeletal radiography NCIT:C137876 NCI Thesaurus (NCIT)
Show evidence (3 references)
PMID:22791401 SUPPORT Human Clinical
"Radiographic signs are relatively mild."
The reason radiographs alone do not reliably prompt the diagnosis.
PMID:22791401 SUPPORT Human Clinical
"The femoral heads are large and the acetabulum forms a distinct "lip" overriding the femoral head."
A specific and distinctive radiographic sign.
PMID:22791401 SUPPORT Human Clinical
"Enlargement of the phalangeal metaphyses develops subtly and is usually recognizable by 10 years."
Gives the radiographic sign and the age at which it becomes readable.
Inflammatory markers and serology to exclude inflammatory arthritis
Normal ESR and CRP with negative RF and ANA. Ordered not to diagnose PPRD but to stop the JIA diagnosis, which is what otherwise happens.
inflammatory marker and autoantibody laboratory panel NCIT:C25294 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:36550675 SUPPORT Human Clinical
"Baseline biochemistry, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor and ANA, were within normal limits."
The panel and its expected result in PPRD.
📈

Progression

4
Clinically silent at birth and in infancy
Age: Birth to about 3 years
The disease is silent at birth and in infancy; height is initially normal. An early-onset subgroup presents before age three with genu varum deformity, which the Turkish cohort identified as an early sign.
Show evidence (2 references)
PMID:22791401 SUPPORT Human Clinical
"The disease is clinically silent at birth and in infancy."
Establishes the asymptomatic early period.
PMID:34919662 SUPPORT Human Clinical
"We observed that genu varum deformity before the age of 3 years was an early sign for PPRD"
Identifies the early-onset presenting sign.
Interphalangeal onset in early childhood
Age: Typically 3 to 6 years
Onset begins with the interphalangeal joints, with joint pain and progressive stiffness. In the classical group the initial symptom was widening of the interphalangeal joints; median age of onset of IP stiffness was 5 years, elbow and knee 9, and hip 12.2.
Show evidence (2 references)
PMID:26610319 SUPPORT Human Clinical
"Onset – typically between ages three and six years – begins with the involvement of the interphalangeal joints."
GeneReviews gives the age and site of onset.
PMID:34919662 SUPPORT Human Clinical
"The median age of onset of IP, elbow, knee and hip stiffness, which became progressive with growth was 5, 9, 9 and 12.2 years, respectively."
Gives the ordered joint-by-joint progression with ages.
Spinal involvement and loss of ambulation
Age: Late childhood and adolescence
Spine involvement develops in late childhood and adolescence, producing a short trunk with thoracolumbar kyphosis; adult height is usually below the third centile. Platyspondyly develops late and can be the first radiographic clue. Nearly half of patients lose independent walking.
Show evidence (2 references)
PMID:22791401 SUPPORT Human Clinical
"Spine involvement develops in late childhood and adolescence leading to short trunk with thoracolumbar kyphosis. Adult height is usually below the 3rd percentile."
Documents the spinal phase and its effect on stature.
PMID:34919662 SUPPORT Human Clinical
"A total of 47.7% lost independent walking ability at the median age of 12 years."
Quantifies the disability endpoint.
Diagnostic delay
Curated as a phase of its own because in this disease the delay is part of the natural history rather than a service-quality footnote. Median onset 4 years, median diagnosis 9.7 years in the Turkish cohort; the review reports that diagnosis is most often made only in the second decade, and that affected children often receive unnecessary anti-inflammatory and immunosuppressive treatment in the interval.
Show evidence (2 references)
PMID:34919662 SUPPORT Human Clinical
"The median age of onset of symptoms and of diagnosis was 4 and 9.7 years, respectively."
Quantifies the delay in a genetically confirmed cohort.
PMID:22791401 SUPPORT Human Clinical
"In spite of the first symptoms appearing in early childhood, the diagnosis of PPRD is most often made only in the second decade and affected children often receive unnecessary anti-inflammatory and immunosuppressive treatments."
States both the delay and the inappropriate treatment that fills it.
📊

Prevalence

1
Worldwide
Unknown 0.1 per 100,000 <1 in 1,000,000
The source gives "one per million" and immediately qualifies it as an underestimate, without a measure type or a denominator. Recorded here as the coarse band with measure_type UNKNOWN rather than promoted to a point prevalence the source does not claim.
Show evidence (1 reference)
PMID:36550675 SUPPORT Human Clinical
"Prevalence underestimated as one per million and most of the cases remain undiagnosed or treated as Juvenile Idiopathic Arthritis (JIA)."
The only published rate, quoted with the author's own caveat.
🌍

Epidemiology

1
Rare and systematically under-ascertained
Prevalence is put at roughly one per million, but that figure is explicitly described as an underestimate because cases are undiagnosed or carried as juvenile idiopathic arthritis. The largest cohorts come from consanguineous or endemic populations — India, China, Turkey, Egypt — each with its own founder or hotspot allele.
Show evidence (1 reference)
PMID:36550675 SUPPORT Human Clinical
"Prevalence underestimated as one per million and most of the cases remain undiagnosed or treated as Juvenile Idiopathic Arthritis (JIA)."
States both the prevalence figure and the reason it is an underestimate.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Progressive Pseudorheumatoid Arthropathy of Childhood:

Juvenile idiopathic arthritis
Overlapping Features The differential that matters, because the error is common, costly and runs in one direction. PPRD patients are routinely diagnosed with and treated for JIA. The discriminators are normal ESR and CRP, negative RF and ANA, bony rather than synovial joint enlargement, platyspondyly, and absent response to anti-inflammatory therapy. Suspecting this should prompt molecular testing rather than escalation of immunosuppression.
Show evidence (2 references)
PMID:34749805 SUPPORT Human Clinical
"Clinical features of progressive pseudorheumatoid dysplasia resemble those of juvenile idiopathic arthritis. Patients with progressive pseudorheumatoid dysplasia are usually misdiagnosed as having juvenile idiopathic arthritis"
States both the resemblance and that misdiagnosis is the usual outcome.
PMID:36550675 SUPPORT Human Clinical
"Baseline biochemistry, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor and ANA, were within normal limits."
Gives the laboratory panel that separates the two.
Czech dysplasia (COL2A1)
Overlapping Features A naming hazard rather than a clinical one, and worth recording because it has already caused a citation error in this repository. "Progressive pseudorheumatoid dysplasia" is used both for this CCN6 recessive disorder and, loosely, for the COL2A1 dominant Czech dysplasia. They are mechanistically unrelated. kb/disorders/Czech_Dysplasia.yaml documents a deep-research report for that entry citing PMID:27587938, which is about the CCN6 disease. Any citation carrying the phrase needs checking against which of the two diseases it actually reports.
Show evidence (1 reference)
PMID:22791401 SUPPORT Human Clinical
"Progressive pseudorheumatoid dysplasia (PPRD) is a genetic, non-inflammatory arthropathy caused by recessive loss of function mutations in WISP3 (Wnt1-inducible signaling pathway protein 3; MIM 603400), encoding for a signaling protein."
Anchors the name used in this entry to the recessive WISP3 disease, which is what distinguishes it from the dominant COL2A1 disorder.
{ }

Source YAML

click to show 
name: Progressive Pseudorheumatoid Arthropathy of Childhood
creation_date: "2026-08-30T06:20:00Z"
category: Mendelian
parents:
- Skeletal Dysplasia
- Spondyloepiphyseal Dysplasia
synonyms:
- PPAC
- PPRD
- progressive pseudorheumatoid dysplasia
- spondyloepiphyseal dysplasia tarda with progressive arthropathy
- SEDT-PA
disease_term:
  preferred_term: progressive pseudorheumatoid arthropathy of childhood
  term:
    id: MONDO:0008827
    label: progressive pseudorheumatoid arthropathy of childhood
description: >-
  Progressive pseudorheumatoid arthropathy of childhood (PPRD) is an autosomal
  recessive skeletal dysplasia caused by biallelic loss-of-function variants in
  CCN6 (WISP3). Articular cartilage degenerates progressively in the complete
  absence of inflammation, producing symmetric joint stiffness and enlargement,
  prominent interphalangeal joints, platyspondyly, short stature and early
  secondary osteoarthritis, with onset typically between three and six years.

  The defining clinical problem is not the arthropathy but the mistake it
  invites. PPRD looks like juvenile idiopathic arthritis and is routinely
  treated as such, sometimes for years, with drugs that cannot work: ESR, CRP,
  rheumatoid factor and ANA are normal, and there is nothing inflammatory for
  an immunosuppressant to act on. In one Turkish cohort the median age at
  symptom onset was four years and at diagnosis 9.7. The cost of that delay is
  measurable — 47.7% of those patients lost independent walking at a median age
  of twelve.

  There is no disease-modifying therapy. Joint arthroplasty for end-stage large
  joints is the one intervention with substantial outcome data behind it.
definitions:
- name: PPRD diagnostic criteria
  definition_type: CASE_DEFINITION
  description: >-
    Established in a proband with characteristic radiographic features and/or
    biallelic pathogenic CCN6 variants. Clinical ascertainment rests on
    progressive stiffness of multiple joints, characteristic wide metaphyses of
    the interphalangeal joints, and platyspondyly.
  scope: Disease-level ascertainment, and separation from inflammatory arthritis.
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of PPRD is established in a proband with characteristic
      radiographic features and/or biallelic pathogenic variants in CCN6
      identified by molecular genetic testing.
    explanation: >-
      GeneReviews states the diagnostic criteria.
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The patients with progressive stiffness of multiple joints, characteristic
      wide metaphysis of interphalangeal (IP) joints and platyspondyly were
      clinically diagnosed with PPRD.
    explanation: >-
      Gives the clinical triad used for ascertainment in a large cohort.
epidemiology:
- name: Rare and systematically under-ascertained
  description: >-
    Prevalence is put at roughly one per million, but that figure is explicitly
    described as an underestimate because cases are undiagnosed or carried as
    juvenile idiopathic arthritis. The largest cohorts come from consanguineous
    or endemic populations — India, China, Turkey, Egypt — each with its own
    founder or hotspot allele.
  evidence:
  - reference: PMID:36550675
    reference_title: A Rare Skeletal Dysplasia-Close Mimicker Of Juvenile Idiopathic Arthritis-Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prevalence underestimated as one per million and most of the cases remain
      undiagnosed or treated as Juvenile Idiopathic Arthritis (JIA).
    explanation: >-
      States both the prevalence figure and the reason it is an underestimate.
prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: BELOW_1_IN_1000000
  rate_per_100000: 0.1
  notes: >-
    The source gives "one per million" and immediately qualifies it as an
    underestimate, without a measure type or a denominator. Recorded here as the
    coarse band with measure_type UNKNOWN rather than promoted to a point
    prevalence the source does not claim.
  evidence:
  - reference: PMID:36550675
    reference_title: A Rare Skeletal Dysplasia-Close Mimicker Of Juvenile Idiopathic Arthritis-Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prevalence underestimated as one per million and most of the cases remain
      undiagnosed or treated as Juvenile Idiopathic Arthritis (JIA).
    explanation: >-
      The only published rate, quoted with the author's own caveat.
progression:
- phase: Clinically silent at birth and in infancy
  age_range: Birth to about 3 years
  notes: >-
    The disease is silent at birth and in infancy; height is initially normal.
    An early-onset subgroup presents before age three with genu varum
    deformity, which the Turkish cohort identified as an early sign.
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease is clinically silent at birth and in infancy.
    explanation: >-
      Establishes the asymptomatic early period.
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We observed that genu varum deformity before the age of 3 years was an
      early sign for PPRD
    explanation: >-
      Identifies the early-onset presenting sign.
- phase: Interphalangeal onset in early childhood
  age_range: Typically 3 to 6 years
  notes: >-
    Onset begins with the interphalangeal joints, with joint pain and
    progressive stiffness. In the classical group the initial symptom was
    widening of the interphalangeal joints; median age of onset of IP stiffness
    was 5 years, elbow and knee 9, and hip 12.2.
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Onset – typically between ages three and six years – begins with the
      involvement of the interphalangeal joints.
    explanation: >-
      GeneReviews gives the age and site of onset.
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median age of onset of IP, elbow, knee and hip stiffness, which became
      progressive with growth was 5, 9, 9 and 12.2 years, respectively.
    explanation: >-
      Gives the ordered joint-by-joint progression with ages.
- phase: Spinal involvement and loss of ambulation
  age_range: Late childhood and adolescence
  notes: >-
    Spine involvement develops in late childhood and adolescence, producing a
    short trunk with thoracolumbar kyphosis; adult height is usually below the
    third centile. Platyspondyly develops late and can be the first radiographic
    clue. Nearly half of patients lose independent walking.
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Spine involvement develops in late childhood and adolescence leading to
      short trunk with thoracolumbar kyphosis. Adult height is usually below the
      3rd percentile.
    explanation: >-
      Documents the spinal phase and its effect on stature.
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 47.7% lost independent walking ability at the median age of 12
      years.
    explanation: >-
      Quantifies the disability endpoint.
- phase: Diagnostic delay
  notes: >-
    Curated as a phase of its own because in this disease the delay is part of
    the natural history rather than a service-quality footnote. Median onset 4
    years, median diagnosis 9.7 years in the Turkish cohort; the review reports
    that diagnosis is most often made only in the second decade, and that
    affected children often receive unnecessary anti-inflammatory and
    immunosuppressive treatment in the interval.
  evidence:
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median age of onset of symptoms and of diagnosis was 4 and 9.7 years,
      respectively.
    explanation: >-
      Quantifies the delay in a genetically confirmed cohort.
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In spite of the first symptoms appearing in early childhood, the diagnosis
      of PPRD is most often made only in the second decade and affected children
      often receive unnecessary anti-inflammatory and immunosuppressive
      treatments.
    explanation: >-
      States both the delay and the inappropriate treatment that fills it.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PPRD is inherited in an autosomal recessive manner.
    explanation: >-
      GeneReviews states the mode of inheritance.
genetic:
- name: CCN6
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: CCN6
    term:
      id: hgnc:12771
      label: CCN6
  notes: >-
    Biallelic loss-of-function CCN6 (WISP3) variants on chromosome 6q22 cause
    PPRD. The mutational spectrum is dominated by single-nucleotide variants and
    small indels and is strongly population-structured, with a distinct founder
    or hotspot allele in each large cohort: c.1010G>A (p.Cys337Tyr) in 10 of 25
    Indian families, c.156C>A (p.Cys52*) in 53.3% of Turkish families, and
    c.624dupA among Chinese patients, where 79% of variants were seen only in
    that population. Two genotype-phenotype signals are reported from the
    Chinese cohort: c.624dupA is associated with later onset, more joints
    involved and elbow predilection, and biallelic null variants with at least
    one in exon 2 with long-bone shortening and severe deformity.
  variants:
  - name: CCN6 c.1010G>A (p.Cys337Tyr)
    description: >-
      The commonest Indian allele, homozygous in 10 unrelated families of 25.
  - name: CCN6 c.156C>A (p.Cys52*)
    description: >-
      Nonsense allele found in 53.3% of Turkish families.
  - name: CCN6 c.624dupA (p.C209Mfs*21)
    description: >-
      Chinese hotspot allele associated with later onset, more extensive joint
      involvement and elbow involvement.
  evidence:
  - reference: PMID:37377052
    reference_title: Clinical and molecular characterization in a cohort of patients with progressive pseudorheumatoid dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PPRD occurs due to loss of function pathogenic variants in WISP3 (CCN6)
      gene, located on chromosome 6q22.
    explanation: >-
      States the causal gene, its locus and the loss-of-function mechanism.
  - reference: PMID:22987568
    reference_title: Analysis of the WISP3 gene in Indian families with progressive pseudorheumatoid dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One missense mutation (c.1010G>A; p.Cys337Tyr) appears to be the most
      common in our population being seen in 10 unrelated families.
    explanation: >-
      Establishes the Indian founder allele and its frequency.
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      c.156C>A(p.Cys52*) variant was found in 53.3% of the families.
    explanation: >-
      Establishes the Turkish founder allele and its frequency.
  - reference: PMID:36622578
    reference_title: "Unique mutation spectrum of progressive pseudorheumatoid dysplasia in the Chinese population: a retrospective genotype-phenotype analysis of 105 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thirty-three variants, including nine novels and five hotspot variants,
      were identified, with 26/33 (79%) variants exclusively seen in the Chinese
      population.
    explanation: >-
      Documents the population-specific structure of the mutational spectrum.
  - reference: PMID:36622578
    reference_title: "Unique mutation spectrum of progressive pseudorheumatoid dysplasia in the Chinese population: a retrospective genotype-phenotype analysis of 105 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among the five hotspot variants, c.624dupA is associated with later onset
      of disease, more extensive joint involvement, and a tendency to affect
      elbow joints.
    explanation: >-
      The reported genotype-phenotype correlation for the Chinese hotspot
      allele.
pathophysiology:
- name: Biallelic CCN6 Loss of Function
  biological_scale: MOLECULAR
  genetic_context:
    gene:
      preferred_term: CCN6
      term:
        id: hgnc:12771
        label: CCN6
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Biallelic nonsense, frameshift, splice-site and missense variants abolish
      CCN6 function. Disease-causing amino-acid substitutions reduce the
      protein's signalling-inhibitory activity in a zebrafish assay.
  evidence:
  - reference: PMID:37377052
    reference_title: Clinical and molecular characterization in a cohort of patients with progressive pseudorheumatoid dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PPRD occurs due to loss of function pathogenic variants in WISP3 (CCN6)
      gene, located on chromosome 6q22.
    explanation: >-
      Names the gene and the loss-of-function mechanism defining this node.
  downstream:
  - target: Loss of CCN6 Modulation of BMP and Wnt Signaling
    causal_link_type: DIRECT
    description: >-
      CCN6 normally inhibits BMP and Wnt signalling by binding BMP ligand and
      the Wnt co-receptors LRP6 and Frizzled; disease alleles reduce that
      inhibition.
    evidence:
    - reference: PMID:17823661
      reference_title: The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Overexpression of zebrafish Wisp3 protein inhibited bone morphogenetic
        protein (BMP) and Wnt signaling in developing zebrafish
      explanation: >-
        Establishes the signalling activity that disease alleles impair.
- name: Loss of CCN6 Modulation of BMP and Wnt Signaling
  biological_scale: MOLECULAR
  description: >-
    CCN6 is a secreted matricellular protein that binds BMP ligand and the Wnt
    co-receptors LRP6 and Frizzled. Loss of that binding removes a brake on both
    pathways in developing and mature cartilage.
  biological_processes:
  - preferred_term: BMP signaling pathway
    modifier: INCREASED
    term:
      id: GO:0030509
      label: BMP signaling pathway
  - preferred_term: Wnt signaling pathway
    modifier: INCREASED
    term:
      id: GO:0016055
      label: Wnt signaling pathway
  evidence:
  - reference: PMID:17823661
    reference_title: The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Overexpression of zebrafish Wisp3 protein inhibited bone morphogenetic
      protein (BMP) and Wnt signaling in developing zebrafish
    explanation: >-
      The inhibitory activity whose loss defines this node, demonstrated by
      gain-of-function in the zebrafish assay.
  downstream:
  - target: Failure of Articular Chondrocyte Matrix Homeostasis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Deregulated BMP/Wnt signalling in cartilage is proposed to disturb
      chondrocyte matrix maintenance, but the intermediate steps between the
      signalling change and cartilage loss are not established in human tissue.
    evidence:
    - reference: PMID:17823661
      reference_title: The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Overexpression of zebrafish Wisp3 protein inhibited bone morphogenetic
        protein (BMP) and Wnt signaling in developing zebrafish
      directness: INDIRECT
      explanation: >-
        The link from this signalling activity to human articular cartilage
        failure is an inference across species and across development; the edge
        is typed accordingly.
- name: Failure of Articular Chondrocyte Matrix Homeostasis
  biological_scale: CELLULAR
  description: >-
    WISP-3 acts on chondrocytes as an autocrine and paracrine ligand,
    upregulating type II collagen and aggrecan and promoting superoxide
    dismutase activity, so its loss removes both a matrix-synthetic and an
    antioxidant input. A separate proposal is that mutant WISP3 loses its
    ability to restrain IGF-1, increasing chondrocyte IGF-1 sensitivity and
    shifting cells toward hypertrophic differentiation. These are complementary
    hypotheses rather than an established sequence.
  cell_types:
  - preferred_term: articular chondrocyte
    term:
      id: CL:1001607
      label: articular chondrocyte
  evidence:
  - reference: PMID:16480948
    reference_title: WISP-3 functions as a ligand and promotes superoxide dismutase activity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      WISP-3 may also promote superoxide dismutase expression and activity in
      chondrocytes
    explanation: >-
      Establishes an antioxidant function of the protein in the affected cell
      type. The authors' own hedge is preserved.
  downstream:
  - target: Progressive Noninflammatory Articular Cartilage Loss
    causal_link_type: DIRECT
    description: >-
      Loss of chondrocyte matrix maintenance produces progressive narrowing of
      all articular spaces as cartilage is lost.
    evidence:
    - reference: PMID:22791401
      reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        There is a progressive narrowing of all articular spaces as articular
        cartilage is lost.
      explanation: >-
        The radiographic observation of the cartilage loss this edge produces.
- name: Progressive Noninflammatory Articular Cartilage Loss
  biological_scale: TISSUE
  description: >-
    Articular cartilage is lost progressively across multiple joints with no
    inflammatory component. The absence of inflammation is not incidental — it
    is what makes anti-inflammatory and immunosuppressive treatment futile, and
    it is the feature that should separate PPRD from juvenile idiopathic
    arthritis at the bedside.
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive pseudorheumatoid dysplasia (PPRD) is a skeletal dysplasia
      characterized by predominant involvement of articular cartilage with
      progressive joint stiffness and enlargement in the absence of
      inflammation.
    explanation: >-
      States both the tissue target and the absence of inflammation.
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      however, signs of inflammation are absent and anti-inflammatory treatment
      is of little help
    explanation: >-
      Connects the absence of inflammation to the failure of anti-inflammatory
      therapy.
  downstream:
  - target: Joint Contracture, Deformity and Loss of Ambulation
    causal_link_type: DIRECT
    description: >-
      Cartilage loss across large joints and the spine causes contractures, gait
      disturbance and spinal deformity, culminating for many patients in loss of
      independent walking.
    evidence:
    - reference: PMID:26610319
      reference_title: Progressive Pseudorheumatoid Dysplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Over time, involvement of large joints and the spine causes significant
        joint contractures, gait disturbance, and scoliosis and/or kyphosis,
        resulting in abnormal posture and significant morbidity.
      explanation: >-
        States the progression from joint involvement to functional morbidity.
- name: Joint Contracture, Deformity and Loss of Ambulation
  biological_scale: ORGANISM
  description: >-
    The functional endpoint. Waddling gait occurred in 97.7% of the Turkish
    cohort and 47.7% lost independent walking at a median age of twelve.
  evidence:
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Waddling gait occurred in 97.7% of the patients. A total of 47.7% lost
      independent walking ability at the median age of 12 years.
    explanation: >-
      Quantifies both the gait abnormality and the loss of ambulation.
phenotypes:
- category: Musculoskeletal
  name: Joint stiffness
  description: >-
    Progressive stiffness of multiple joints, beginning at the interphalangeal
    joints and spreading to elbows, knees and hips.
  phenotype_term:
    preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive pseudorheumatoid dysplasia (PPRD) is a skeletal dysplasia
      characterized by predominant involvement of articular cartilage with
      progressive joint stiffness and enlargement in the absence of
      inflammation.
    explanation: >-
      Names progressive joint stiffness as a defining feature.
- category: Musculoskeletal
  name: Prominent interphalangeal joints
  description: >-
    Characteristic wide metaphyses of the interphalangeal joints, the usual
    first sign in classical-onset disease. Bound to HP:0006237 rather than a
    generic joint-swelling term because the enlargement is bony metaphyseal
    widening, not synovial swelling — which is precisely the distinction from
    inflammatory arthritis.
  phenotype_term:
    preferred_term: Prominent interphalangeal joints
    term:
      id: HP:0006237
      label: Prominent interphalangeal joints
  evidence:
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The initial symptom in the early-onset group was genu varum deformity,
      while it was widening of IP joints in the classical group.
    explanation: >-
      Identifies interphalangeal widening as the presenting sign of classical
      disease.
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bony enlargement at the interphalangeal joints progresses leading to
      camptodactyly.
    explanation: >-
      States that the enlargement is bony, which is the discriminating feature.
- category: Musculoskeletal
  name: Platyspondyly
  description: >-
    Flattened vertebral bodies developing in late childhood; can be the first
    radiographic clue to the diagnosis.
  phenotype_term:
    preferred_term: Platyspondyly
    term:
      id: HP:0000926
      label: Platyspondyly
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Platyspondyly develops in late childhood and can be the first clue to the
      diagnosis.
    explanation: >-
      States the finding, its timing and its diagnostic value.
- category: Musculoskeletal
  name: Waddling gait
  phenotype_term:
    preferred_term: Waddling gait
    term:
      id: HP:0002515
      label: Waddling gait
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Waddling gait occurred in 97.7% of the patients.
    explanation: >-
      Gives an explicit denominator-backed frequency in a genetically confirmed
      cohort.
- category: Growth
  name: Short stature
  description: >-
    Height is normal initially and falls below the third centile in adolescence
    as the skeletal changes progress.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Initially height is normal; however, short stature (<3rd centile) becomes
      evident in adolescence as the skeletal changes progress.
    explanation: >-
      Establishes the phenotype and its late emergence.
- category: Musculoskeletal
  name: Osteoarthritis
  description: >-
    Secondary osteoarthritis follows cartilage loss and is the source of the
    pain that drives treatment.
  phenotype_term:
    preferred_term: Osteoarthritis
    term:
      id: HP:0002758
      label: Osteoarthritis
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pain due to secondary osteoarthritis may respond to nonsteroidal
      anti-inflammatory drugs.
    explanation: >-
      GeneReviews names secondary osteoarthritis as a manifestation requiring
      treatment.
- category: Musculoskeletal
  name: Genu varum
  description: >-
    The presenting sign of the early-onset form, appearing before age three.
  phenotype_term:
    preferred_term: Genu varum
    term:
      id: HP:0002970
      label: Genu varum
  evidence:
  - reference: PMID:34919662
    reference_title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We observed that genu varum deformity before the age of 3 years was an
      early sign for PPRD
    explanation: >-
      Identifies genu varum as the early-onset presenting sign.
- category: Musculoskeletal
  name: Osteoporosis
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:22987568
    reference_title: Analysis of the WISP3 gene in Indian families with progressive pseudorheumatoid dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive pseudorheumatoid dysplasia (PPD) is a progressive skeletal
      syndrome characterized by stiffness, swelling and pain in multiple joints
      with associated osteoporosis in affected patients.
    explanation: >-
      Names osteoporosis among the defining features.
- category: Musculoskeletal
  name: Camptodactyly
  description: >-
    Fixed flexion of the interphalangeal joints, the endpoint of progressive
    bony enlargement at those joints.
  phenotype_term:
    preferred_term: Camptodactyly
    term:
      id: HP:0012385
      label: Camptodactyly
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bony enlargement at the interphalangeal joints progresses leading to
      camptodactyly.
    explanation: >-
      States camptodactyly as the consequence of the interphalangeal
      enlargement, which is why it is curated as a separate phenotype rather
      than folded into it.
- category: Musculoskeletal
  name: Kyphosis
  description: >-
    Thoracolumbar kyphosis develops with spinal involvement in late childhood
    and adolescence, producing the short trunk.
  phenotype_term:
    preferred_term: Kyphosis
    term:
      id: HP:0002808
      label: Kyphosis
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Spine involvement develops in late childhood and adolescence leading to
      short trunk with thoracolumbar kyphosis.
    explanation: >-
      Names thoracolumbar kyphosis and its timing.
- category: Musculoskeletal
  name: Scoliosis
  description: >-
    Scoliosis accompanies the kyphosis as spinal involvement accrues, and is
    the deformity the bracing treatment in this entry is aimed at.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Over time, involvement of large joints and the spine causes significant
      joint contractures, gait disturbance, and scoliosis and/or kyphosis,
      resulting in abnormal posture and significant morbidity.
    explanation: >-
      The same GeneReviews sentence that grounds the kyphosis and contracture
      phenotypes names scoliosis alongside them.
- category: Musculoskeletal
  name: Joint contractures
  description: >-
    Significant joint contractures follow large-joint and spinal involvement and
    are a principal source of the functional morbidity.
  phenotype_term:
    preferred_term: Joint contracture
    term:
      id: HP:0034392
      label: Joint contracture
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Over time, involvement of large joints and the spine causes significant
      joint contractures, gait disturbance, and scoliosis and/or kyphosis,
      resulting in abnormal posture and significant morbidity.
    explanation: >-
      GeneReviews names joint contractures among the accruing morbidity.
- category: Musculoskeletal
  name: Contractures of the small joints of the hands
  description: >-
    Swelling of the small joints of the hands and contractures are the commonest
    presenting features in the Indian series.
  phenotype_term:
    preferred_term: Finger joint contracture
    term:
      id: HP:0034681
      label: Finger joint contracture
  evidence:
  - reference: PMID:22987568
    reference_title: Analysis of the WISP3 gene in Indian families with progressive pseudorheumatoid dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Swelling of small joints of hands and contractures are the most common
      presenting features.
    explanation: >-
      Identifies small-joint swelling and contracture as the commonest
      presentation in a 35-patient series.
biochemical:
- name: Inflammatory markers and autoantibody serology
  presence: NORMAL
  notes: >-
    ESR, CRP, rheumatoid factor and ANA are within normal limits. This is a
    negative finding curated deliberately: it is the single most useful
    discriminator from juvenile idiopathic arthritis, and its normality is why
    immunosuppression cannot work.
  evidence:
  - reference: PMID:36550675
    reference_title: A Rare Skeletal Dysplasia-Close Mimicker Of Juvenile Idiopathic Arthritis-Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Baseline biochemistry, erythrocyte sedimentation rate (ESR), C-reactive
      protein (CRP), rheumatoid factor and ANA, were within normal limits.
    explanation: >-
      Documents the normal inflammatory and serological panel in a genetically
      confirmed case.
diagnosis:
- name: Molecular genetic testing of CCN6
  diagnosis_term:
    preferred_term: CCN6 molecular genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    Definitive confirmation. Mutation analysis confirmed the diagnosis in 63 of
    64 typical cases in one series, so a negative result in a clinically typical
    patient is unusual and should prompt the cDNA route below rather than
    abandonment of the diagnosis.
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutation analysis of WISP3 allowed the confirmation of the diagnosis in 63
      out of 64 typical cases in our series.
    explanation: >-
      Quantifies the diagnostic yield of sequencing in clinically typical
      patients.
- name: Skin biopsy and fibroblast cDNA analysis for intronic splice variants
  diagnosis_term:
    preferred_term: skin biopsy for fibroblast cDNA analysis
    term:
      id: NCIT:C51692
      label: Skin Biopsy
  description: >-
    The step most likely to be missed. Intronic CCN6 variants causing splicing
    aberrations are detectable only in cDNA from fibroblasts, so a skin biopsy
    is indicated when genomic analysis is negative in an otherwise typical
    patient. Without it, a genuine case can be dismissed on a normal sequencing
    result.
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intronic mutations in WISP3 leading to splicing aberrations can be
      detected only in cDNA from fibroblasts and therefore a skin biopsy is
      indicated when genomic analysis fails to reveal mutations in individuals
      with otherwise typical signs and symptoms.
    explanation: >-
      States both the limitation of genomic testing and the specific remedy.
- name: Radiographic assessment
  diagnosis_term:
    preferred_term: skeletal radiography
    term:
      id: NCIT:C137876
      label: Bone Radiography
  description: >-
    Radiographic signs are relatively mild, which is part of why the diagnosis
    is missed. The specific findings are platyspondyly in late childhood,
    phalangeal metaphyseal enlargement usually recognisable by ten years, large
    femoral heads with an acetabular lip overriding the head, and progressive
    narrowing of all articular spaces.
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Radiographic signs are relatively mild.
    explanation: >-
      The reason radiographs alone do not reliably prompt the diagnosis.
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The femoral heads are large and the acetabulum forms a distinct "lip"
      overriding the femoral head.
    explanation: >-
      A specific and distinctive radiographic sign.
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Enlargement of the phalangeal metaphyses develops subtly and is usually
      recognizable by 10 years.
    explanation: >-
      Gives the radiographic sign and the age at which it becomes readable.
- name: Inflammatory markers and serology to exclude inflammatory arthritis
  diagnosis_term:
    preferred_term: inflammatory marker and autoantibody laboratory panel
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  description: >-
    Normal ESR and CRP with negative RF and ANA. Ordered not to diagnose PPRD
    but to stop the JIA diagnosis, which is what otherwise happens.
  evidence:
  - reference: PMID:36550675
    reference_title: A Rare Skeletal Dysplasia-Close Mimicker Of Juvenile Idiopathic Arthritis-Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Baseline biochemistry, erythrocyte sedimentation rate (ESR), C-reactive
      protein (CRP), rheumatoid factor and ANA, were within normal limits.
    explanation: >-
      The panel and its expected result in PPRD.
treatments:
- name: Total Hip Arthroplasty
  description: >-
    The one intervention in PPRD with substantial outcome data. In four
    genetically confirmed patients undergoing one-stage bilateral total hip
    arthroplasty, Harris Hip Score rose from 39.67 to 91.67 and SF-36 from 19.67
    to 71.33 over a mean 47.9 months, with no aseptic loosening. Named for the
    hip rather than for joint replacement generally: GeneReviews recommends
    arthroplasty for severe joint pain from advanced osteoarthritis without
    naming a joint, but every outcome figure quoted here is from hip series, so
    the broader name would claim a scope the evidence does not cover.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: total hip arthroplasty
    term:
      id: NCIT:C51691
      label: Arthroplasty
  target_mechanisms:
  - target: Joint Contracture, Deformity and Loss of Ambulation
    treatment_effect: BYPASSES
    description: >-
      Arthroplasty replaces the destroyed joint rather than acting on the
      cartilage-loss process, so it restores function without altering the
      disease. That is why it is a BYPASSES link, and why it does not stop
      progression at other joints.
    evidence:
    - reference: PMID:31876842
      reference_title: Mid-Term Outcome of Total Hip Arthroplasty in Patients With Progressive Pseudorheumatoid Dysplasia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This study indicated that THA was effective to treat the PPD patients
        complicated with hip arthropathy with satisfactory clinical and
        radiological outcome after mid-term follow-up.
      explanation: >-
        Reports the functional outcome of replacing the affected joint.
  evidence:
  - reference: PMID:31876842
    reference_title: Mid-Term Outcome of Total Hip Arthroplasty in Patients With Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Harris Hip Score increased from 39.67 ± 9.73 points preoperatively to
      91.67 ± 4.32 points postoperatively (p < 0.05); Short Form 36 increased
      from 19.67 ± 1.53 points preoperatively to 71.33 ± 3.06 postoperatively (p
      < 0.05).
    explanation: >-
      Quantifies the functional and quality-of-life gain.
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Severe joint pain due to advanced osteoarthritis is treated by joint
      arthroplasty.
    explanation: >-
      GeneReviews states the indication.
- name: Physical Therapy and Activity Modification
  description: >-
    Large-joint stiffness is managed by physical therapy, activity modification
    and walking aids; small-joint arthropathy by occupational therapy with
    adaptive devices. What the activity modification has to avoid is the
    reflexive orthopaedic response to a stiff, painful joint: GeneReviews lists
    immobilization, casting specifically, under agents and circumstances to
    avoid, so the caution belongs to this treatment rather than sitting in the
    entry's notes.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Large joint stiffness is managed by physical therapy, activity
      modification, and walking aids.
    explanation: >-
      GeneReviews states the supportive management for joint stiffness.
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Agents/circumstances to avoid: Immobilization (e.g., casting).
    explanation: >-
      Grounds the activity-modification arm of this treatment: the modification
      that matters is avoiding immobilization.
- name: NSAID Analgesia for Secondary Osteoarthritis
  description: >-
    NSAIDs are used for pain from secondary osteoarthritis. Note the careful
    distinction GeneReviews draws: they are for osteoarthritic pain, not for a
    disease process, and they do not modify the arthropathy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pain due to secondary osteoarthritis may respond to nonsteroidal
      anti-inflammatory drugs.
    explanation: >-
      GeneReviews states the analgesic indication and hedges the response.
- name: Vitamin D Supplementation in Documented Deficiency
  description: >-
    GeneReviews recommends supplementation in those with vitamin D deficiency.
    This is correction of a coincident deficiency, not a disease-modifying
    therapy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Nutritional Support
    term:
      id: NCIT:C15433
      label: Nutritional Support
    therapeutic_agent:
    - preferred_term: calcitriol
      term:
        id: CHEBI:17823
        label: calcitriol
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In those with vitamin D deficiency, supplementation is recommended.
    explanation: >-
      GeneReviews states the indication, conditioned on documented deficiency.
- name: Genetic Counseling and Carrier Testing
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If the CCN6 pathogenic variants have been identified in an affected family
      member, carrier testing for at-risk relatives and prenatalpreimplantation
      genetic testing are possible.
    explanation: >-
      GeneReviews states the available reproductive genetic options.
- name: Immunosuppressants and DMARDs
  description: >-
    Modelled explicitly as an ineffective therapy rather than left as prose,
    because prescribing it is the characteristic clinical error in this disease
    and the entry should be queryable for that. There is no inflammatory process
    for these drugs to suppress; the misdiagnosis as juvenile idiopathic
    arthritis is what leads to years of them. Modality is OTHER rather than
    SMALL_MOLECULE because the class as prescribed here spans conventional
    synthetic DMARDs, corticosteroids and biologic agents, so no single platform
    describes it.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Progressive Noninflammatory Articular Cartilage Loss
    treatment_effect: MODULATES
    description: >-
      No effect. Anti-inflammatory and immunosuppressive treatment does not act
      on this node because the node has no inflammatory component.
    evidence:
    - reference: PMID:22791401
      reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
      supports: REFUTE
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        however, signs of inflammation are absent and anti-inflammatory
        treatment is of little help
      explanation: >-
        Graded REFUTE against the claim that this treatment acts on the
        cartilage-loss node; the source states directly that it does not help.
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      affected children often receive unnecessary anti-inflammatory and
      immunosuppressive treatments
    explanation: >-
      Records that these drugs are given and are unnecessary, which is the claim
      this treatment entry exists to carry.
- name: Bracing for Scoliosis and Mild Kyphosis
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: bracing
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Scoliosis and mild kyphosis may be treated with bracing.
    explanation: >-
      GeneReviews management recommendation for the spinal deformity.
- name: Surgical Correction of Angular Lower-Limb Deformity
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: orthopedic surgical procedure
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Surgical treatment for angular deformities of the lower limbs per
      orthopedic surgeon.
    explanation: >-
      GeneReviews management recommendation for limb deformity.
- name: Occupational Therapy and Adaptive Devices
  description: >-
    Small-joint arthropathy is managed by an occupational therapist advising
    adaptive devices, activity modification and vocational training.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: occupational therapy
    term:
      id: NCIT:C121351
      label: Occupational Therapy
  evidence:
  - reference: PMID:26610319
    reference_title: Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Small joint arthropathy is managed by an occupational therapist who may
      advise adaptive devices, modification of activity, and/or vocational
      training.
    explanation: >-
      GeneReviews management recommendation for small-joint disease.
differential_diagnoses:
- name: Juvenile idiopathic arthritis
  description: >-
    The differential that matters, because the error is common, costly and runs
    in one direction. PPRD patients are routinely diagnosed with and treated for
    JIA. The discriminators are normal ESR and CRP, negative RF and ANA, bony
    rather than synovial joint enlargement, platyspondyly, and absent response
    to anti-inflammatory therapy. Suspecting this should prompt molecular
    testing rather than escalation of immunosuppression.
  evidence:
  - reference: PMID:34749805
    reference_title: "Progressive pseudorheumatoid dysplasia misdiagnosed as juvenile idiopathic arthritis: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical features of progressive pseudorheumatoid dysplasia resemble those
      of juvenile idiopathic arthritis. Patients with progressive
      pseudorheumatoid dysplasia are usually misdiagnosed as having juvenile
      idiopathic arthritis
    explanation: >-
      States both the resemblance and that misdiagnosis is the usual outcome.
  - reference: PMID:36550675
    reference_title: A Rare Skeletal Dysplasia-Close Mimicker Of Juvenile Idiopathic Arthritis-Progressive Pseudorheumatoid Dysplasia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Baseline biochemistry, erythrocyte sedimentation rate (ESR), C-reactive
      protein (CRP), rheumatoid factor and ANA, were within normal limits.
    explanation: >-
      Gives the laboratory panel that separates the two.
- name: Czech dysplasia (COL2A1)
  description: >-
    A naming hazard rather than a clinical one, and worth recording because it
    has already caused a citation error in this repository. "Progressive
    pseudorheumatoid dysplasia" is used both for this CCN6 recessive disorder
    and, loosely, for the COL2A1 dominant Czech dysplasia. They are
    mechanistically unrelated. kb/disorders/Czech_Dysplasia.yaml documents a
    deep-research report for that entry citing PMID:27587938, which is about the
    CCN6 disease. Any citation carrying the phrase needs checking against which
    of the two diseases it actually reports.
  evidence:
  - reference: PMID:22791401
    reference_title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive pseudorheumatoid dysplasia (PPRD) is a genetic,
      non-inflammatory arthropathy caused by recessive loss of function
      mutations in WISP3 (Wnt1-inducible signaling pathway protein 3; MIM
      603400), encoding for a signaling protein.
    explanation: >-
      Anchors the name used in this entry to the recessive WISP3 disease, which
      is what distinguishes it from the dominant COL2A1 disorder.
discussions:
- discussion_id: no_mouse_model_for_ccn6_loss
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Wisp3-deficient mice have no apparent phenotype. What does a species with no
    disease tell us about the human mechanism, and what model should replace the
    mouse for preclinical work?
  attaches_to:
  - pathophysiology#Loss of CCN6 Modulation of BMP and Wnt Signaling
  rationale: >-
    This is a translational block rather than a gap in evidence. Loss of Wisp3
    in the mouse produces no apparent phenotype, and neither does overexpression
    — so the standard preclinical species is uninformative for a disease that is
    fully penetrant in humans. Two readings are open. Either mouse cartilage has
    a redundancy that human articular cartilage lacks, in which case the
    interesting biology is what compensates; or the human phenotype depends on
    mechanical loading histories, growth duration or joint geometry that a mouse
    does not reproduce. The zebrafish work is currently the only in vivo system
    where CCN6 loss does something, and it reports pharyngeal cartilage
    morphology rather than progressive articular degeneration. Until this is
    resolved there is no animal system in which a disease-modifying therapy
    could be tested, which is a plausible part of why none exists.
  evidence:
  - reference: PMID:17823661
    reference_title: The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      in mice there is no apparent phenotype caused by Wisp3 deficiency or
      overexpression
    explanation: >-
      The negative result that constitutes the mismatch.
- discussion_id: bmp_wnt_to_cartilage_loss_intermediates
  kind: KNOWLEDGE_GAP
  prompt: >-
    What are the intermediate steps between deregulated BMP/Wnt signalling and
    progressive loss of human articular cartilage in PPRD?
  attaches_to:
  - pathophysiology#Failure of Articular Chondrocyte Matrix Homeostasis
  rationale: >-
    Both ends of this chain are well supported and the middle is not. CCN6's
    inhibition of BMP and Wnt signalling is demonstrated by gain-of-function in
    zebrafish; progressive articular cartilage loss is documented
    radiographically in patients. Between them sit at least three competing
    proposals — loss of matrix-synthetic drive on type II collagen and aggrecan,
    loss of superoxide dismutase-dependent antioxidant protection, and
    increased chondrocyte IGF-1 sensitivity driving hypertrophic differentiation
    — none demonstrated in human articular cartilage. They are not mutually
    exclusive, which is part of why none has been excluded. The edge in this
    entry is typed INDIRECT_UNKNOWN_INTERMEDIATES for exactly this reason.
  evidence:
  - reference: PMID:16480948
    reference_title: WISP-3 functions as a ligand and promotes superoxide dismutase activity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      WISP-3 may also promote superoxide dismutase expression and activity in
      chondrocytes
    explanation: >-
      One of the competing intermediate proposals, stated with the authors' own
      hedge.
references:
- reference: PMID:26610319
  title: Progressive Pseudorheumatoid Dysplasia.
  tags:
  - GeneReviews
- reference: PMID:34919662
  title: "Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort."
- reference: PMID:22791401
  title: "The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals."
notes: >-
  Naming hazard, recorded because this repository has already been bitten by it.
  "Progressive pseudorheumatoid dysplasia" names both this CCN6 recessive
  disorder and, loosely, the COL2A1 dominant Czech dysplasia.
  kb/disorders/Czech_Dysplasia.yaml carries a note that a deep-research report
  generated for that entry cited PMID:27587938, which is about the CCN6 disease.
  Every citation used here was checked against which of the two diseases the
  paper actually reports; PMID:27587938 is not cited in this entry, and the
  cross-reference is curated as a differential_diagnoses entry so the confusion
  is discoverable from either side.

  Deep research: eight wrong ontology bindings in one report. One OpenScientist
  report was generated (research/Progressive_Pseudorheumatoid_Arthropathy_Of_Childhood-deep-research-openscientist.md)
  and contributed most of the cohort literature used here. Its reference
  validation was clean — 29/29 verified, confabulation rate 0.0 — but its term
  validation set needs_review: true with 14 label mismatches, of which eight
  were CURIEs naming entirely different concepts. None was used:

  - MONDO:0009215 suggested as the disease term; it is Fanconi anemia
    complementation group A. This entry uses MONDO:0008827, the stub's term,
    which was independently confirmed by OAK lookup.
  - HP:0000944 for platyspondyly; it is Abnormal metaphysis morphology.
    HP:0000926 is used here.
  - HP:0100360 for enlarged interphalangeal joints; it is Upper-limb joint
    contracture. HP:0006237 is used here.
  - HP:0002826 for spinal canal stenosis; it is Halberd-shaped pelvis. No spinal
    stenosis phenotype is curated.
  - NCIT:C157866 for total hip arthroplasty; it is Gluten Free Diet.
    NCIT:C51691 is used here.
  - NCIT:C51765 for physical therapy; it is Bilateral Salpingectomy with
    Oophorectomy. NCIT:C15302 is used here.
  - NCIT:C1898 for calcitriol; it is Physical Carcinogens. CHEBI:17823 is used
    here as a therapeutic_agent.
  - UBERON:0002217 for articular cartilage and UBERON:0003656 for
    interphalangeal joint resolve to synovial joint and mesopodium bone
    respectively. No UBERON terms are bound in this entry.

  Every CURIE used in this entry was checked against the committed term cache or
  looked up directly with OAK, and none was copied from the report.

  Care guidance from GeneReviews that is recorded here rather than as a
  treatment, because none of it is an intervention with a mechanism target.
  Deformities of the pelvis may necessitate delivery by caesarean
  section. Surveillance is orthopaedic: assessment for bone deformity, secondary
  joint disease, spinal deformity and pain at each visit, with annual evaluation
  by a skeletal dysplasia specialist.

  Deliberately not curated. No
  histopathology section: the cited sources describe radiographic joint-space
  narrowing rather than tissue-level findings. No datasets. No model_organism
  animal_models entry, because the informative animal result here is the
  zebrafish morpholino work and the mouse null result, and both are curated as a
  discussion rather than as a model card — the mouse has no phenotype to link a
  modeled_mechanisms readout to, and the zebrafish reports pharyngeal cartilage
  morphology rather than the articular degeneration this disease is about.

  Frequency bands are given only for joint stiffness and waddling gait, where a
  denominator-backed figure or an "in the absence of inflammation" defining
  statement supports one.
📚

References & Deep Research

References

3
PMID:26610319
Progressive Pseudorheumatoid Dysplasia.
No top-level findings curated for this source.
PMID:34919662
Specific early signs and long-term follow-up findings of progressive pseudorheumatoid dysplasia (PPRD) in the Turkish cohort.
No top-level findings curated for this source.
PMID:22791401
The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Record notes

Naming hazard, recorded because this repository has already been bitten by it. "Progressive pseudorheumatoid dysplasia" names both this CCN6 recessive disorder and, loosely, the COL2A1 dominant Czech dysplasia. kb/disorders/Czech_Dysplasia.yaml carries a note that a deep-research report generated for that entry cited PMID:27587938, which is about the CCN6 disease. Every citation used here was checked against which of the two diseases the paper actually reports; PMID:27587938 is not cited in this entry, and the cross-reference is curated as a differential_diagnoses entry so the confusion is discoverable from either side. Deep research: eight wrong ontology bindings in one report. One OpenScientist report was generated (research/Progressive_Pseudorheumatoid_Arthropathy_Of_Childhood-deep-research-openscientist.md) and contributed most of the cohort literature used here. Its reference validation was clean — 29/29 verified, confabulation rate 0.0 — but its term validation set needs_review: true with 14 label mismatches, of which eight were CURIEs naming entirely different concepts. None was used: - MONDO:0009215 suggested as the disease term; it is Fanconi anemia complementation group A. This entry uses MONDO:0008827, the stub's term, which was independently confirmed by OAK lookup. - HP:0000944 for platyspondyly; it is Abnormal metaphysis morphology. HP:0000926 is used here. - HP:0100360 for enlarged interphalangeal joints; it is Upper-limb joint contracture. HP:0006237 is used here. - HP:0002826 for spinal canal stenosis; it is Halberd-shaped pelvis. No spinal stenosis phenotype is curated. - NCIT:C157866 for total hip arthroplasty; it is Gluten Free Diet. NCIT:C51691 is used here. - NCIT:C51765 for physical therapy; it is Bilateral Salpingectomy with Oophorectomy. NCIT:C15302 is used here. - NCIT:C1898 for calcitriol; it is Physical Carcinogens. CHEBI:17823 is used here as a therapeutic_agent. - UBERON:0002217 for articular cartilage and UBERON:0003656 for interphalangeal joint resolve to synovial joint and mesopodium bone respectively. No UBERON terms are bound in this entry. Every CURIE used in this entry was checked against the committed term cache or looked up directly with OAK, and none was copied from the report. Care guidance from GeneReviews that is recorded here rather than as a treatment, because none of it is an intervention with a mechanism target. Deformities of the pelvis may necessitate delivery by caesarean section. Surveillance is orthopaedic: assessment for bone deformity, secondary joint disease, spinal deformity and pain at each visit, with annual evaluation by a skeletal dysplasia specialist. Deliberately not curated. No histopathology section: the cited sources describe radiographic joint-space narrowing rather than tissue-level findings. No datasets. No model_organism animal_models entry, because the informative animal result here is the zebrafish morpholino work and the mouse null result, and both are curated as a discussion rather than as a model card — the mouse has no phenotype to link a modeled_mechanisms readout to, and the zebrafish reports pharyngeal cartilage morphology rather than the articular degeneration this disease is about. Frequency bands are given only for joint stiffness and waddling gait, where a denominator-backed figure or an "in the absence of inflammation" defining statement supports one.

Create: Progressive Pseudorheumatoid Arthropathy of Childhood · 2026-08-30T07:02:06Z · View source

De novo curation of progressive pseudorheumatoid arthropathy of childhood (MONDO:0008827, CCN6/WISP3), using GeneReviews PMID:26610319 as the phenotype baseline plus four national cohorts (Turkey, China, India, Egypt). One OpenScientist deep-research report was generated and read. Its reference validation was clean (29/29 verified) but its term validation set needs_review with 14 label mismatches, of which eight were CURIEs naming entirely different concepts. None was used: MONDO:0009215 as the disease term (it is Fanconi anemia complementation group A, confirmed by OAK lookup), HP:0000944 for platyspondyly (Abnormal metaphysis morphology), HP:0100360 for enlarged interphalangeal joints (Upper-limb joint contracture), HP:0002826 for spinal canal stenosis (Halberd-shaped pelvis), NCIT:C157866 for total hip arthroplasty (Gluten Free Diet), NCIT:C51765 for physical therapy (Bilateral Salpingectomy with Oophorectomy), NCIT:C1898 for calcitriol (Physical Carcinogens), and two UBERON terms. Every CURIE in the entry was instead checked against the committed term cache or looked up directly with OAK. The Czech dysplasia naming hazard already recorded in kb/disorders/Czech_Dysplasia.yaml was cross-referenced as a differential_diagnoses entry rather than re-derived; PMID:27587938, the citation that entry flags as misattributed, is not cited here. Two reference titles were corrected after the validator flagged mismatches against the cached records. Validated with just validate (50/50 snippets verified), check-entity-refs, check-duplicate-keys, check-snippet-length, check-title-snippets, check-snippet-grading and check-folded-hyphens.

OpenScientist ▸
Progressive Pseudorheumatoid Arthropathy of Childhood (PPRD): A Comprehensive Disease Characteristics Report
openscientist-autonomous 29 citations 2026-08-30T06:37:57.618960

Progressive Pseudorheumatoid Arthropathy of Childhood (PPRD): A Comprehensive Disease Characteristics Report

Disease: Progressive Pseudorheumatoid Arthropathy of Childhood (synonyms: Progressive Pseudorheumatoid Dysplasia, PPRD/PPD; Spondyloepiphyseal Dysplasia Tarda with Progressive Arthropathy, SEDT-PA) Category: Mendelian, autosomal recessive OMIM: 208230 · Causal gene: WISP3/CCN6 (chr6q22) Suggested MONDO: MONDO:0009215

Summary

Progressive Pseudorheumatoid Arthropathy of Childhood — more commonly termed progressive pseudorheumatoid dysplasia (PPRD) — is a rare autosomal recessive skeletal dysplasia caused by biallelic loss-of-function variants in the WISP3/CCN6 gene on chromosome 6q22. CCN6 encodes a secreted, modular matricellular protein of the CCN family that modulates BMP and Wnt signaling and supports articular-chondrocyte homeostasis. When its function is lost, the articular cartilage of multiple joints progressively degenerates in a noninflammatory fashion, producing the disease's hallmark presentation: symmetric polyarticular stiffness and enlargement, "knobbly" interphalangeal joints, platyspondyly, short stature, waddling gait, and early secondary osteoarthritis, with onset typically between ages 3 and 8 years.

The single most clinically important feature of PPRD is that it closely mimics juvenile idiopathic arthritis (JIA) and is very frequently misdiagnosed as such. Unlike JIA, however, inflammatory markers (ESR, CRP) are normal and serologies (RF, ACPA, ANA, HLA-B27) are negative. This distinction matters therapeutically: because the disease is noninflammatory, immunosuppressants, DMARDs, and biologics are ineffective, and patients are often exposed to years of unnecessary treatment before the correct molecular diagnosis is established by whole-exome sequencing or targeted gene panels. Radiographic clues — platyspondyly with intravertebral herniations, epiphyseal/metaphyseal changes, and enlarged interphalangeal joints — combined with normal inflammatory parameters and a compatible family history should prompt molecular testing.

There is currently no disease-modifying pharmacotherapy for PPRD. Management is entirely supportive: analgesia/NSAIDs, physiotherapy, calcium/vitamin D (with calcitriol for documented deficiency), genetic counseling, and, for end-stage large-joint disease, joint arthroplasty, which produces durable functional and quality-of-life gains. Lifespan is generally normal, but the disability burden is high — roughly half of patients lose independent ambulation by adolescence. This report synthesizes nine confirmed findings and 36 reviewed papers into a full disease-characteristics profile spanning etiology, phenotype, molecular mechanism, epidemiology, diagnosis, prognosis, treatment, prevention, and model systems.

Key Findings

Finding 1 — PPRD is caused by biallelic loss-of-function variants in WISP3/CCN6 (chr6q22), inherited autosomal recessively

PPRD is a monogenic Mendelian disorder. Multiple independent cohorts have confirmed that biallelic pathogenic variants in WISP3 (also designated CCN6), located on chromosome 6q22, cause the disease through loss of function. As stated directly in the Egyptian cohort report: "PPRD occurs due to loss of function pathogenic variants in WISP3 (CCN6) gene, located on chromosome 6q22" (PMID: 37377052).

The mutational spectrum is broad and dominated by single-nucleotide variants and small indels, with variants concentrated in exons 2, 4, and 5. Representative cohort data are summarized below:

Cohort N patients Distinct variants Notable/founder alleles PMID
Egypt 23 11 (5 novel): nonsense (p.L27*, p.Q126*), frameshift (p.C54fs*12), missense (p.Leu246Pro), splice (IVS3-1G>A) — 37377052
China 105 33 (79% Chinese-exclusive) c.624dupA (hotspot; later onset) 36622578
India 35 (25 families) — c.1010G>A (p.Cys337Tyr) in 10 families 22987568
Turkey 44 — c.156C>A (p.Cys52*) in 53.3% of families 34919662

A genotype–phenotype correlation has been documented in the Chinese population: "Among the five hotspot variants, c.624dupA is associated with later onset of disease, more extensive joint involvement, and a tendency to affect elbow joints" (PMID: 36622578). The Indian founder allele is likewise well established: "One missense mutation (c.1010G>A; p.Cys337Tyr) appears to be the most common in our population being seen in 10 unrelated families" (PMID: 22987568). Although nearly all reported variants are SNVs or small indels, a copy-number deletion in trans with a single-nucleotide variant has also been reported in monozygotic twins, detected only by genome sequencing after a 13-year diagnostic odyssey (PMID: 38958524).

Ontology suggestions: Gene HGNC WISP3/CCN6; inheritance HP:0000007 (Autosomal recessive inheritance).

Finding 2 — PPRD is a noninflammatory progressive arthropathy frequently misdiagnosed as juvenile idiopathic arthritis

Clinically, PPRD presents in childhood with symmetric polyarticular stiffness and enlargement, characteristic "knobbly" interphalangeal joints, gait abnormality, platyspondyly, short stature, and early secondary osteoarthritis with osteoporosis. In the Turkish cohort, median symptom onset was ~4 years but median age at diagnosis was 9.7 years, underscoring diagnostic delay. Gait involvement is nearly universal and disability accrues over time: "Waddling gait occurred in 97.7% of the patients. A total of 47.7% lost independent walking ability at the median age of 12 years" (PMID: 34919662). Genu varum before age 3 is described as an early sign of the early-onset form.

Crucially, laboratory inflammatory markers are normal (ESR/CRP within range) and serologies are negative (RF, ACPA, ANA, HLA-B27), distinguishing PPRD from true inflammatory arthritides (PMID: 39539552, PMID: 34749805). Despite this, the clinical resemblance to JIA leads to frequent misdiagnosis: "Clinical features of progressive pseudorheumatoid dysplasia resemble those of juvenile idiopathic arthritis. Patients with progressive pseudorheumatoid dysplasia are usually misdiagnosed as having juvenile idiopathic arthritis" (PMID: 34749805). Consequently, patients are often inappropriately treated with methotrexate and biologics before the correct diagnosis (PMID: 32894151).

Ontology suggestions: HP:0002758 (Osteoarthritis), HP:0001387 (Joint stiffness), HP:0000944 (Platyspondyly), HP:0000939 (Osteoporosis), HP:0002515 (Waddling gait), HP:0004322 (Short stature), HP:0100360 (Enlarged interphalangeal joints).

Finding 3 — WISP3/CCN6 modulates BMP and Wnt signaling and supports cartilage homeostasis

The molecular function of CCN6 has been most clearly defined in zebrafish. Overexpression of zebrafish Wisp3 inhibits both BMP and Wnt signaling by binding BMP ligand and Wnt co-receptors LRP6/Frizzled; disease-causing amino-acid substitutions reduce this inhibitory activity, and morpholino knockdown alters pharyngeal cartilage size and shape (PMID: 17823661). As stated: "Overexpression of zebrafish Wisp3 protein inhibited bone morphogenetic protein (BMP) and Wnt signaling in developing zebrafish."

In chondrocytes, WISP-3 acts as an autocrine/paracrine ligand and upregulates type II collagen, aggrecan, and superoxide dismutase (SOD) activity, linking it to both matrix maintenance and antioxidant defense: "WISP-3 may also promote superoxide dismutase expression and activity in chondrocytes" (PMID: 16480948). A mechanistic hypothesis proposes that mutant WISP3 loses its ability to inhibit IGF-1, increasing chondrocyte sensitivity to IGF-1 and driving a shift toward hypertrophic differentiation and apoptosis (PMID: 17363178).

Notably, the mouse model does not recapitulate the disease: "in mice there is no apparent phenotype caused by Wisp3 deficiency or overexpression" (PMID: 17823661) — a critical limitation for translational research (see Model Organisms, Section 15).

Ontology suggestions: GO:0030509 (BMP signaling pathway), GO:0016055 (Wnt signaling pathway), GO:0051216 (cartilage development), GO:0005520 (insulin-like growth factor binding); CL:0000138 (chondrocyte).

Finding 4 — No disease-modifying pharmacotherapy exists; management is supportive, with joint replacement effective for end-stage disease

There is no specific pharmacological treatment for PPRD; care is supportive — analgesia/NSAIDs, physiotherapy, calcium/vitamin D, calcitriol, and genetic counseling (PMID: 38862149, PMID: 34674084). Because the disease is noninflammatory, immunosuppressants and DMARDs are ineffective (PMID: 37417608). As stated plainly: "Its diagnosis is only confirmed by genetic testing, and no specific pharmacological treatment is still available" (PMID: 38862149).

For end-stage hip and knee disease, total joint arthroplasty provides durable benefit. In four genetically confirmed PPRD patients undergoing total hip arthroplasty, functional and quality-of-life scores improved substantially: "Harris Hip Score increased from 39.67 ± 9.73 points preoperatively to 91.67 ± 4.32 points postoperatively (p < 0.05); Short Form 36 increased from 19.67 ± 1.53 points preoperatively to 71.33 ± 3.06 postoperatively (p < 0.05)" at a mean follow-up of 47.9 months, with no aseptic loosening (PMID: 31876842). Multi-joint replacement (bilateral hips, knees, and ankle) has restored function even in young patients (PMID: 38681928, PMID: 38862149). Calcitriol for documented low 25-OH vitamin D stabilized or improved joints in a small series (PMID: 34674084).

Ontology suggestions: NCIT:C157866 (Total Hip Arthroplasty), NCIT:C51765 (Physical Therapy), NCIT:C1898 (Calcitriol/Vitamin D), NCIT:C1505 (Calcium supplement).

Finding 5 — PPRD is a rare disease (~1 per million estimated), underdiagnosed, with founder variants in consanguineous populations

The estimated prevalence is approximately 1 per 1,000,000, but this figure is widely regarded as an underestimate due to frequent misdiagnosis as JIA: "Prevalence underestimated as one per million and most of the cases remain undiagnosed or treated as Juvenile Idiopathic Arthritis (JIA)" (PMID: 36550675). The largest cohorts derive from consanguineous or endemic populations — India, China, Turkey, and Egypt — each with population-specific hotspot/founder alleles (c.1010G>A in India, c.156C>A in 53.3% of Turkish families, c.624dupA in China). Autosomal recessive inheritance means consanguinity elevates risk.

The radiographic hallmarks that support diagnosis are well documented: "Radiographic and magnetic resonance imaging of the cases revealed typical features characteristic for PPD-like platyspondyly, multiple intravertebral herniations, changes in metaphyses and epiphysis" (PMID: 15877179).

Finding 6 — WISP3/CCN6 is a secreted matricellular CCN-family protein with modular IGFBP–VWC–TSP1–CT domains; disease variants disrupt conserved cysteines

CCN6 (WISP3) is one of six CCN matricellular proteins (CCN1–CCN6). Each shares a conserved modular architecture: "The proteins consist of 4 motifs, a signal peptide (for secretion) followed consecutively by the IGFBP, VWC, TSP1 and CT (C-terminal cysteine knot domain) motifs" (PMID: 27517291). These modules mediate binding to growth factors, extracellular matrix, integrins, and receptors. The N-terminal IGFBP-like module is the structural basis for the proposed IGF-1 sensitization mechanism (PMID: 17363178).

Many PPRD-causing variants are nonsense or frameshift changes producing loss of function, while missense variants frequently substitute conserved cysteines that form the disulfide bonds stabilizing these modules (e.g., p.Cys52*, p.Cys337Tyr, p.C54fs) (PMID: 22987568, PMID: 34919662, PMID: 37377052).

Ontology suggestions: GO:0005576 (extracellular region), GO:0005520 (insulin-like growth factor binding), GO:0031012 (extracellular matrix).

Finding 7 — PPRD belongs to a group of skeletal-dysplasia "rheumatic mimics" requiring molecular diagnosis to avoid misclassification as JIA

PPRD is one of several genetic skeletal dysplasias whose musculoskeletal presentation mimics rheumatic disease. In a Southeastern Turkey cohort of 47 individuals from 22 families with noninflammatory musculoskeletal complaints, molecular testing identified PPRD in 7 patients alongside other JIA mimics: Camptodactyly–Arthropathy–Coxa Vara–Pericarditis syndrome (n=12, PRG4), Hereditary Multiple Exostoses (n=9), Trichorhinophalangeal syndrome (n=5), Spondyloenchondrodysplasia with immune dysregulation (n=6), Pseudoachondroplasia (n=3, COMP), MPS VI, and others (PMID: 40626694). As the authors note: "Their musculoskeletal manifestations frequently mimic those of rheumatic diseases, especially Juvenile Idiopathic Arthritis (JIA), complicating accurate diagnosis", and "Progressive Pseudorheumatoid Dysplasia (n = 7)" was confirmed molecularly.

A PPRD-like phenotype can also arise from a heterozygous COL2A1 variant, producing a type II collagenopathy overlapping with SED Stanescu type — an important differential to consider when WISP3 testing is negative (PMID: 26183434).

Finding 8 — Wide expressivity from severe early-onset to delayed adult presentation; spinal canal stenosis may require surgery

Although classic onset is between 3 and 8 years — "characterized by pain, stiffness and enlargement of multiple joints with an age of onset between 3 and 8 years old" (PMID: 29246200) — the phenotype spans a wide clinical spectrum. At the severe end, neglected early-onset cases present with marked muscle wasting and weakness (PMID: 29258992); at the mild end, delayed adult presentations occur, such as a 35-year-old man with a ~20-year history diagnosed via compound WISP3 variants (c.670dupA + c.756C>A/p.Cys252*) (PMID: 29246200) and a 53-year-old affected relative in an Iraqi-Jewish family carrying p.C86F (PMID: 30922245).

Spinal involvement can progress to canal stenosis requiring surgery: "we present a Chinese man with PPD who underwent spinal surgery twice because of canal stenosis and related symptoms caused by the disease" (homozygous c.395G>A/p.C132Y; PMID: 30635069). Severe early scoliosis has also been reported (PMID: 26991965). Across the literature, diagnosis is repeatedly established by WES or gene panels once clinical suspicion is high (PMID: 30922245, PMID: 29258992, PMID: 32894151).

Ontology suggestions: HP:0002826 (Spinal canal stenosis), HP:0002650 (Scoliosis), HP:0002751 (Kyphoscoliosis).

Finding 9 — No disease-modifying drug pipeline, pharmacogenomic markers, or validated omics biomarkers exist (evidence gap)

Targeted literature searches for therapeutic-target/drug-development, chondroprotection, and disease-modifying pharmacotherapy in PPRD return no primary reports; reviews and case series consistently affirm that no specific pharmacological treatment exists (PMID: 38862149, PMID: 30327864). No registered disease-specific interventional trials of disease-modifying agents were identified. There are no established transcriptomic, proteomic, or metabolomic patient biomarkers; the only mechanistic omics-adjacent work is in vitro chondrocyte regulation of collagen II/aggrecan/SOD (PMID: 16480948) and a 2025 study of the molecular consequences of CCN6 variants (PMID: 41009407). Pharmacogenomics is not applicable because there is no disease-specific drug therapy.

Section-by-Section Disease Profile

1. Disease Information

PPRD is a rare, autosomal recessive, noninflammatory skeletal dysplasia characterized by progressive degeneration of articular cartilage across multiple joints, producing pain, stiffness, joint enlargement, platyspondyly, and short stature. Key identifiers: OMIM 208230; suggested MONDO:0009215; the gene is WISP3/CCN6. Synonyms/alternative names: Progressive Pseudorheumatoid Dysplasia (PPRD/PPD); Spondyloepiphyseal Dysplasia Tarda with Progressive Arthropathy (SEDT-PA); Arthropathy, Progressive Pseudorheumatoid, of Childhood (APPRC). Information is derived primarily from aggregated disease-level resources — cohort studies, case series, and case reports — rather than EHR-derived individual patient records.

2. Etiology

The primary cause is genetic: biallelic loss-of-function variants in WISP3/CCN6 (Finding 1). No environmental, infectious, or mechanical cause initiates the disease. Genetic risk factors: the causal variants themselves; population-specific founder/hotspot alleles increase incidence in certain groups (c.1010G>A India, c.156C>A Turkey, c.624dupA China). Environmental risk/protective factors: none established; consanguinity is a demographic risk factor for recessive disease inheritance. Vitamin D deficiency is a modifiable comorbidity that may worsen skeletal outcomes and should be corrected (PMID: 34674084). No gene–environment interactions are documented.

3. Phenotypes

Core phenotypes (with suggested HPO terms and qualitative frequency):

Phenotype Type HPO suggestion Onset Frequency
Symmetric polyarticular stiffness/enlargement Clinical sign HP:0001387 Childhood Very frequent
Enlarged ("knobbly") interphalangeal joints Physical HP:0100360 Childhood Very frequent
Waddling gait Clinical sign HP:0002515 Childhood 97.7% (PMID: 34919662)
Loss of independent ambulation Functional — Adolescence 47.7% by median age 12
Platyspondyly / intravertebral herniations Radiographic HP:0000944 Childhood Frequent
Short stature Physical HP:0004322 Childhood Frequent
Early secondary osteoarthritis Clinical HP:0002758 Childhood–adolescence Frequent
Osteoporosis / reduced BMD Laboratory/imaging HP:0000939 Childhood Frequent
Genu varum (early-onset form) Physical HP:0002970 <3 yr Early sign
Spinal canal stenosis / scoliosis Complication HP:0002826 / HP:0002650 Variable Subset
Normal inflammatory markers/serology Laboratory — — Characteristic

Quality of life: substantial impairment — chronic pain, progressive joint contracture, and loss of ambulation in ~half of patients by adolescence markedly reduce daily functioning; arthroplasty improves SF-36 scores dramatically (PMID: 31876842).

4. Genetic/Molecular Information

Causal gene: WISP3/CCN6 (OMIM 603400), chr6q22. Variant classification: the majority are pathogenic/likely pathogenic per ACMG/AMP; >70 variants reported, concentrated in exons 2, 4, and 5 (PMID: 30327864). Variant types: nonsense, frameshift, missense (frequently conserved-cysteine substitutions), splice-site, and — rarely — copy-number deletions (PMID: 38958524). Allele frequency: individually very rare in gnomAD; founder alleles enriched regionally. Origin: germline. Functional consequence: loss of function (Findings 1, 6). Intronic splice variants may require mRNA analysis from cultured skin fibroblasts when genomic-DNA screening is negative (PMID: 30327864). Modifier genes: none firmly established, though genotype (e.g., c.624dupA) correlates with onset timing. Incidental MEFV variants have been co-reported but are not modifiers of PPRD per se (PMID: 32894151). Epigenetics / chromosomal abnormalities: none characteristic.

5. Environmental Information

Not applicable as a cause — PPRD is monogenic. No environmental toxins, lifestyle factors, or infectious agents contribute to onset. Vitamin D status is the only modifiable environmental co-factor relevant to management.

6. Mechanism / Pathophysiology

Molecular pathways: CCN6 normally inhibits BMP and Wnt signaling and supports chondrocyte matrix synthesis (type II collagen, aggrecan) and antioxidant defense (SOD) (Findings 3, 6). Proposed causal chain: loss-of-function CCN6 → dysregulated BMP/Wnt signaling and increased chondrocyte sensitivity to IGF-1 → shift of articular chondrocytes toward hypertrophic/terminal differentiation and apoptosis, with reduced type II/IX collagen → progressive noninflammatory cartilage degeneration → secondary osteoarthritis, joint enlargement, platyspondyly, and disability (PMID: 17363178, PMID: 16480948). Cellular processes: chondrocyte apoptosis, hypertrophic differentiation, matrix homeostasis failure, possible oxidative stress (loss of SOD support). Immune involvement: none — the disease is noninflammatory. Metabolic changes: none characteristic beyond local cartilage matrix metabolism.

LOF CCN6/WISP3 (biallelic)
│
▼
Loss of BMP/Wnt inhibition + increased IGF-1 sensitivity
│
▼
Articular chondrocyte hypertrophic shift → apoptosis
│
▼
Progressive NON-inflammatory cartilage degeneration
│
├──► Enlarged interphalangeal joints, joint stiffness
├──► Platyspondyly, intravertebral herniation, short stature
└──► Early secondary osteoarthritis → disability / loss of ambulation

GO/CL suggestions: GO:0030509 (BMP signaling), GO:0016055 (Wnt signaling), GO:0051216 (cartilage development), GO:0006915 (apoptotic process); CL:0000138 (chondrocyte), CL:0000743 (articular chondrocyte).

7. Anatomical Structures Affected

Primary organ/system: the skeletal system, specifically the articular cartilage of multiple synovial joints (interphalangeal joints, hips, knees, elbows, ankles, shoulders, wrists) and the vertebral column (platyspondyly, intravertebral herniation, canal stenosis). Secondary involvement: secondary osteoarthritis, muscle wasting/weakness in severe cases. Tissue/cell level: hyaline articular cartilage; articular chondrocytes (CL:0000743). Subcellular: the secreted protein acts extracellularly (GO:0005576, extracellular region/matrix). Localization: symmetric and bilateral joint involvement is characteristic. UBERON suggestions: UBERON:0002217 (articular cartilage of joint), UBERON:0001474 (bone element), UBERON:0001130 (vertebral column), UBERON:0003656 (interphalangeal joint).

8. Temporal Development

Onset: typically pediatric, ages 3–8 years, but ranges from severe early-onset (<3 yr, genu varum) to delayed adult presentation (PMID: 29246200, PMID: 30922245). Onset pattern: insidious, chronic. Progression: slowly progressive over years; ~48% lose independent ambulation by median age 12. Course: progressive, lifelong; no spontaneous remission. Critical periods: early diagnosis (childhood) is the key window to avoid inappropriate immunosuppressive treatment and to institute supportive care; end-stage large-joint disease is the window for arthroplasty.

9. Inheritance and Population

Inheritance: autosomal recessive. Penetrance: high/complete for biallelic LOF, with variable expressivity (Finding 8). Prevalence: ~1/1,000,000, likely underestimated (PMID: 36550675, PMID: 30200995). Founder effects/consanguinity: documented in India, Turkey, China, Egypt, and an Iraqi-Jewish family; consanguinity increases risk. Sex ratio: no strong sex bias reported (autosomal). Anticipation/mosaicism: not features of this disorder.

10. Diagnostics

Laboratory: inflammatory markers (ESR, CRP) normal; RF, ACPA, ANA, HLA-B27 negative — a key discriminator from JIA. Imaging: skeletal survey / lateral spine radiograph showing platyspondyly, intravertebral herniations, epiphyseal/metaphyseal changes, and enlarged interphalangeal joints; MRI may show joint changes (PMID: 15877179). Genetic testing (definitive): single-gene WISP3 sequencing, skeletal-dysplasia gene panels, or WES/WGS; genome sequencing detects CNVs missed by other methods (PMID: 38958524); mRNA analysis from skin-fibroblast culture is needed for intronic splice variants (PMID: 30327864). Clinical criteria: clinical suspicion from symmetric noninflammatory polyarthropathy + knobbly IP joints + gait abnormality + normal inflammatory markers + characteristic radiographs, confirmed molecularly. Differential diagnosis: JIA (primary mimic), Camptodactyly–Arthropathy–Coxa Vara–Pericarditis syndrome (PRG4), pseudoachondroplasia (COMP), mucopolysaccharidoses, SED Stanescu-type / COL2A1 type II collagenopathy, and other skeletal dysplasias (PMID: 40626694, PMID: 26183434).

11. Outcome/Prognosis

Survival: lifespan is generally normal (PMID: 30200995). Morbidity: high disability — progressive joint contracture, chronic pain, and loss of independent ambulation in ~48% by adolescence. Complications: severe secondary osteoarthritis, spinal canal stenosis, scoliosis, muscle wasting. Quality of life: markedly reduced; substantially improved after arthroplasty (SF-36 ~20→71) (PMID: 31876842). Prognostic factors: genotype (e.g., c.624dupA → later onset), age at diagnosis, and access to supportive/surgical care.

12. Treatment

Pharmacotherapy: none disease-modifying; symptomatic analgesia/NSAIDs, calcium/vitamin D, calcitriol for deficiency (PMID: 34674084). Immunosuppressants/DMARDs/biologics are ineffective and should be avoided (PMID: 37417608). Surgical/interventional: total hip/knee arthroplasty and multi-joint replacement for end-stage disease with durable benefit (NCIT:C157866); spinal decompression/correction for canal stenosis or scoliosis (PMID: 31876842, PMID: 38681928, PMID: 30635069). Rehabilitative/supportive: physiotherapy, occupational therapy, mobility aids, pain management. Pharmacogenomics: not applicable. Experimental: no registered disease-modifying trials identified.

13. Prevention

Primary prevention: genetic counseling for at-risk (especially consanguineous) families; carrier testing and, where appropriate, prenatal or preimplantation genetic diagnosis once the familial variant is known. Secondary prevention: early molecular diagnosis to avoid unnecessary immunosuppression and to initiate timely supportive care. Tertiary prevention: physiotherapy, vitamin D optimization, and well-timed arthroplasty to preserve function and prevent complications. No vaccine, behavioral, or population-based public-health intervention applies.

14. Other Species / Natural Disease

Orthologs of WISP3/CCN6 exist across vertebrates (human, mouse Wisp3, zebrafish wisp3). No naturally occurring animal disease counterpart is documented (no established OMIA entry in the reviewed literature). Zebrafish require Wisp3 for normal pharyngeal cartilage development, whereas mice show no phenotype — a striking species divergence relevant to evolutionary conservation of the mechanism (PMID: 17823661). No zoonotic or cross-species transmission applies (non-infectious disease).

15. Model Organisms

Model Phenotype recapitulation Utility PMID
Mouse Wisp3 KO / overexpression No apparent phenotype — does not model the disease Limited; a major translational gap 17823661
Zebrafish (morpholino knockdown / overexpression) Alters pharyngeal cartilage size/shape; demonstrates BMP/Wnt modulation Best available in vivo system for mechanism 17823661
In vitro chondrocytes WISP-3 regulates collagen II, aggrecan, SOD; IGF-1 sensitivity Mechanistic dissection of cartilage biology 16480948, 17363178

The lack of a phenotypic mouse model is the principal limitation for preclinical therapeutic development; patient-derived iPSC-chondrocytes or organoids represent a logical next step but were not found in the reviewed literature.

Mechanistic Model / Interpretation

PPRD is best understood as a cartilage-autonomous, noninflammatory chondrodysplasia driven by loss of a single secreted regulator of joint-cartilage homeostasis. The unifying model places CCN6/WISP3 at a signaling node that restrains BMP, Wnt, and IGF-1 activity in articular chondrocytes and simultaneously supports matrix synthesis (type II collagen, aggrecan) and antioxidant defense (SOD). Biallelic loss of function removes these brakes, tipping chondrocytes toward hypertrophic terminal differentiation and apoptosis — the same fate normally reserved for growth-plate chondrocytes, now occurring inappropriately in permanent articular cartilage. The result is relentless, symmetric cartilage attrition with secondary osteoarthritis, joint enlargement, and vertebral (platyspondyly) changes, but without immune-mediated inflammation — which is why serologies and acute-phase reactants remain normal and why anti-inflammatory/immunosuppressive therapy fails.

This mechanistic picture directly explains the disease's dominant clinical problem — misdiagnosis as JIA — and its therapeutic corollary: only supportive and reconstructive (surgical) management alters outcomes, because the primary lesion is structural cartilage loss, not inflammation. The variable expressivity (severe childhood to mild adult forms) likely reflects residual/hypomorphic protein function tied to specific genotypes (e.g., c.624dupA → later onset), a hypothesis supported by cohort genotype–phenotype correlations.

Evidence Base

PMID Contribution Supports finding
37377052 Egyptian cohort; gene, locus, LOF mechanism, 11 variants F1, F6
36622578 Chinese cohort (105); genotype–phenotype (c.624dupA) F1
22987568 Indian cohort; founder allele c.1010G>A F1, F6
34919662 Turkish cohort; gait 97.7%, disability, founder c.156C>A F2, F5
34749805 Documents JIA misdiagnosis pitfall F2
17823661 Zebrafish BMP/Wnt modulation; mouse null phenotype F3, F15
16480948 WISP-3 as ligand; SOD, collagen II, aggrecan F3, F9
17363178 IGF-1 sensitization hypothesis F3, F6
31876842 THA outcomes: HHS 40→92, SF-36 20→71 F4
38862149 No pharmacotherapy; diagnosis genetic only F4, F9
27517291 CCN modular domain architecture F6
40626694 PPRD among genetic rheumatic mimics F7
26183434 COL2A1 PPRD-like phenocopy F7
30635069 Spinal canal stenosis requiring surgery F8
29246200 Age of onset 3–8 yr; delayed adult case F8
36550675 Prevalence ~1/million, underdiagnosis F5
15877179 Radiographic diagnostic features F5
38958524 CNV in trans; GS + deep phenotyping F1
34674084 Calcitriol for vitamin D deficiency F4
30327864 Review; >70 variants; mRNA testing for splice variants F9

Evidence source types span human clinical cohorts and case series (majority), model organism (zebrafish, mouse), in vitro chondrocyte studies, and computational/genomic variant analyses.

Limitations and Knowledge Gaps

  1. No disease-modifying therapy or drug pipeline. All treatment is supportive/surgical; no targeted agent, RNA therapy, or gene therapy has been trialed (F9).
  2. No phenotypic mouse model. Wisp3-null mice are asymptomatic, hampering preclinical development; zebrafish and in vitro chondrocytes are the only usable systems (F3, F15).
  3. No validated biomarkers. No transcriptomic, proteomic, or metabolomic patient biomarker exists for diagnosis, staging, or prognosis (F9).
  4. Prevalence uncertainty. The ~1/million estimate is unreliable due to systematic misdiagnosis; true prevalence is likely higher (F5).
  5. Incomplete genotype–phenotype maps. Beyond a few hotspot alleles, determinants of severity/onset are poorly resolved; modifier genes are unidentified.
  6. Mechanistic gaps. The IGF-1 sensitization model remains a hypothesis; the precise postnatal role of CCN6 in cartilage homeostasis is not fully defined.

Proposed Follow-up Experiments / Actions

  1. Develop patient-derived iPSC-chondrocyte and cartilage-organoid models to overcome the mouse phenotype gap and enable mechanistic dissection and drug screening.
  2. Test rescue of BMP/Wnt/IGF-1 dysregulation (e.g., pathway modulators) in zebrafish and iPSC-chondrocyte systems as candidate chondroprotective strategies.
  3. Establish an international PPRD registry with standardized deep phenotyping and genome sequencing to refine prevalence, natural history, and genotype–phenotype correlations.
  4. Discover circulating biomarkers — measure CCN6 and cartilage-turnover markers (e.g., CTX-II, COMP) longitudinally to enable early diagnosis and progression monitoring.
  5. Systematize early diagnostic pathways in pediatric rheumatology (normal inflammatory markers + symmetric noninflammatory polyarthropathy + platyspondyly → reflex WISP3/panel testing) to shorten diagnostic delay and prevent inappropriate immunosuppression.
  6. Long-term arthroplasty outcome studies in young PPRD patients to optimize implant selection, timing, and multi-joint strategies.
  7. Evaluate variant-specific effects (including the newer c.348C>A, c.676G>C, and CNV alleles) on protein secretion/function to inform prognosis and future precision approaches.

Report compiled from 9 confirmed findings and 36 reviewed publications across a multi-iteration autonomous investigation. Ontology suggestions (HPO, GO, CL, UBERON, NCIT, MONDO) are provided throughout to support knowledge-base curation.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 29
Resolved 29
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 29
On topic 25
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 30
Resolved 30
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0
Terms whose name was checked 29
Terms named correctly 11
Terms named as a different term 14
Terms whose name is worth a second look 4

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • HP:0002758 (2 mentions) - the report calls it "Osteoarthritis", "Clinical"; HP calls it Osteoarthritis
  • HP:0001387 (2 mentions) - the report calls it "Joint stiffness", "Clinical sign"; HP calls it Joint stiffness
  • HP:0000944 (2 mentions) - the report calls it "Platyspondyly", "Radiographic"; HP calls it Abnormal metaphysis morphology
  • HP:0000939 (2 mentions) - the report calls it "Osteoporosis", "Laboratory/imaging"; HP calls it Osteoporosis
  • HP:0002515 (2 mentions) - the report calls it "Waddling gait", "Clinical sign"; HP calls it Waddling gait
  • HP:0004322 (2 mentions) - the report calls it "Short stature", "Physical"; HP calls it Short stature
  • HP:0100360 (2 mentions) - the report calls it "Enlarged interphalangeal joints", "Physical"; HP calls it Upper-limb joint contracture
  • NCIT:C157866 (2 mentions) - the report calls it "Total Hip Arthroplasty"; NCIT calls it Gluten Free Diet
  • NCIT:C51765 (1 mention) - the report calls it "Physical Therapy"; NCIT calls it Bilateral Salpingectomy with Oophorectomy
  • NCIT:C1898 (1 mention) - the report calls it "Calcitriol/Vitamin D"; NCIT calls it Physical Carcinogens
  • HP:0002826 (2 mentions) - the report calls it "Spinal canal stenosis"; HP calls it Halberd-shaped pelvis
  • HP:0002970 (1 mention) - the report calls it "Physical"; HP calls it Genu varum
  • UBERON:0002217 (1 mention) - the report calls it "articular cartilage of joint"; UBERON calls it synovial joint
  • UBERON:0003656 (1 mention) - the report calls it "interphalangeal joint"; UBERON calls it mesopodium bone

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • GO:0030509 (2 mentions) - the report calls it "BMP signaling pathway", "BMP signaling"; GO calls it BMP signaling pathway
  • GO:0016055 (2 mentions) - the report calls it "Wnt signaling pathway", "Wnt signaling"; GO calls it Wnt signaling pathway
  • NCIT:C1505 (1 mention) - the report calls it "Calcium supplement"; NCIT calls it Dietary Supplement, and lists "Supplement" among its other names
  • CL:0000743 (2 mentions) - the report calls it "articular chondrocyte"; CL calls it hypertrophic chondrocyte

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • HP:0002758 - called "Osteoarthritis", "Clinical"
  • HP:0001387 - called "Joint stiffness", "Clinical sign"
  • HP:0000944 - called "Platyspondyly", "Radiographic"
  • HP:0000939 - called "Osteoporosis", "Laboratory/imaging"
  • HP:0002515 - called "Waddling gait", "Clinical sign"
  • HP:0004322 - called "Short stature", "Physical"
  • HP:0100360 - called "Enlarged interphalangeal joints", "Physical"
  • GO:0030509 - called "BMP signaling pathway", "BMP signaling"
  • GO:0016055 - called "Wnt signaling pathway", "Wnt signaling"